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Th i s  s tudy was c ondu c t ed to det erm i ne i f  M i vacur i um 
( M i v )  was as e f f e c t i ve as Vecuron i um ( Ve e )  i n  att enuat i ng 
Su c c i ny l cho l i ne ( Sc h ) - i nduced fas c i cu lat i ons w i th mu s c l e  
r e l axant doses based upon i dea l body we i ght ( I BW) . A qua s i ­
exper i menta l de s i gn was used t o  s tudy 6 0  pat i en t s  who were 
random l y  a s s i gned t o  one o f  three groups . The two s tudy 
groups were c ompared t o  a cont r o l  group and each other w i th 
regards to the i nc i dence and i ntens i t y o f  fas c i c u l a t i ons . 
E i ther Vee ( 0 . 0 1 mg/kg ( IBW ) ) ,  M i v  ( 0 . 0 2 mg/kg ( I B W ) ) ,  or 
sal i ne ( contro l )  wa s adm i n i s t ered in a doub l e - b l i nded manner 
3 m i nutes pr i or an i ntubat i ng dose o f  Sch ( I BW) . Both 
pretreatment moda l i t i e s r e s u l ted in a s i g n i f i cant ( E  < . 0 5 )  
decreas e  i n  the i nc i dence ( Ve e  40% , M i v  6 0%) and i n tens i t y 
i x  
o f  fas c i cu l at i ons when compared to s a l i ne ( 9 0 % ) .  No 
s i gn i f i cant d i f f erences (£ > .05) were f ound between the two 
pretreatment groups w i th r egards to the i nc i dence and 
i nt en s i t y of fa s c i c u l a t i ons . I t  was conc l uded that M i v  0.0 2  
mg/kg ( I BW )  att enuated Sch- i nduced f as c i c u l at i ons w i th the 
same e f f i c a c y  as Vee 0.0 1 mg/kg ( I BW) . 
Chapt er One 
Introduct i on 
S i nce the i ntroduct i on o f  neuromuscu lar b l ock i ng drug s  
i nt o  c l i n i ca l  ane s the s i a , t h e  s earch f or t h e  i dea l musc l e  
re laxant has never ceased . Curare , a natura l l y  occurr i ng 
p l an t  a l ka l o i d ,  was d i scovered i n  the South Amer i can j ung l e  
where i t  was u s ed by Amazon ian i nd ians a s  a n  arrow po i son t o  
para l yze the i r  pre y . It was the f ir s t  neuromuscu lar 
b l ock i n g  drug used a s  an a d j unct to ane s the s ia b y  Gr i f f i th 
and Johnson ( 1 94 2 ) .  A l though curare opened a new era i n  
modern ane s th e s ia ,  i t  d i d  not take l ong b e f ore d i sadvantages 
were recogn i z ed , two o f  wh i ch were the l ong durat i on o f  
muscle relaxat i on and t h e  re l ea s e  o f  h i s tam i ne ( Le e , 1 9 84 ; 
M i l l er ,  1 9 8 9 ; Morgan & M i kha i l ,  1 9 9 2 ; Sco t t  & Savar e s e , 
1 9 8 4 ) . Once these d i sadvantages were d i scovered the s earch 
began f or the i dea l musc l e  re laxant . 
A mu l t i tude o f  drugs were s ynthe s i zed i n  an at t empt t o  
produce musc l e  re l axat i on w i thout detri menta l s i de e f fect s . 
One of the s e  drugs was s ucc i ny lcho l i ne ( Sch ) . Fo l d e s  ( 1 9 5 2 )  
i ntroduced Sch i nt o  c l i n ical anesthe s i a  prac t ice i n  the 
Un i ted Sta t e s. One o f  the mo s t  i mportant advantages o f  Sch 
1 
i s  i t s' rap i d  onset o f  a c t i on wh i ch i s  l e s s  than 1 m i nute . 
Even today , more than 4 1  years later , there i s  no mus c l e  
re l axant ava i lab l e  w i th such a comparab l e  ons e t  o f  a c t i on 
( Le e , 1 9 8 4 ; M i l l er & Savare s e , 1 9 9 0 ; Stoe l t i ng , 1 9 9 1) .  
2 
At the t i me of i t s  c l i n i ca l  debu t , Sch c l o s e l y  
res emb l ed the i dea l mus c l e  re laxant . It had a fas t  onset , a 
rap i d  and comp l ete rec overy , and a c on tro l lab l e  i ntens i ty .  
D i sadvantag e s  were not eas i l y  re cogn ized because most o f  the 
s i de e f f e c t s were spec i f i c  t o  S c h . A l though the i n c i dence 
and s ever i t y o f  c omp l i cat i ons f o l l ow i ng the u s e  of 
Sch was h i gh ,  it has reta i ned i ts popu lar i t y b e cause Sch 
rema i n s  the on l y  mus c l e  re l axant that prov i d e s  e xc e l l en t  
i ntubat i ng c ond i t i ons w i t h i n  1 m i nute and c omp l ete rec overy 
w i th i n  1 0  m i nutes (Bevan & Donat i ,  1 9 8 5 ; M i l l er ,  1 9 8 9 ; 
Morgan & M i kha i l , 1 9 9 2) .  
Mos t  o f  the s er i ou s  s i de e f f e c t s  a s s o c iated w i th Sch 
are a re s u l t  o f  its  e f f e c t  o n  the myoneura l j un c t i on . The 
l i s t  of s i de e f f e c t s  i n c l ude : ( 1) mus c l e  fas c i cu lat i on s , 
( 2) postopera t i v e  mya l g i a , (3) i n crea s e d  i ntraga s tr i c  
pre s s ure , ( 4) i n creased i ntracran i a l  pre s s ure , ( 5) i ncreased 
i ntraoc u l ar pre s s ure , and ( 6 )  hyperka l em ia ( Be van & Donat i ,  
1 9 8 5 ; Lebow i tz & Rams ey , 1 9 8 9 ; Lee , 1 9 8 4 ; M i l l er & Savare s e , 
1 9 9 0 ; Stoe l t i ng & M i l l er ,  1 9 8 9) .  Severa l treatment reg i me s  
were emp l oyed to avo i d  t h e s e  prob l em s . They i n c l uded the 
adm i n i s trat i on o f  s ma l l  s ubpara l yt i c  do s e s  of 
nondepo lar i z i ng mus c l e  re l axan t s  ( NDMR) such a s  D-
3 
tubocurarine, pancuron i um, ga l l am i ne, atra cur i um, and 
ve curon i um .  Suc c iny l cho l ine i tse l f  has a l so been used i n  
sma l l  "se l f -tam i ng" doses . Most of these reg i mes met w i th 
var y i ng degrees of suc cess i n  attenuat i ng the f as c i cu l at i ons 
and postoperat ive mya l g i as ( Bevan & Donat i ,  1 9 8 5 ; M i l l e r , 
1 9 8 9 ; Sto e l t ing & M i l l e r , 1 9 8 9 ) . A l though there was not a 
c l ear r e l at i onsh i p  between the seve r ity of the 
f asc i c u l at i ons and the i ntens ity of the p ostope rat i v e  
mya lg i as ; the abo l it i on o f  f as c i cu l at i ons by p r i or 
adm i n i strat i on of a subpara l yt i c  dose o f  a NDMR d e c reased 
the i n c i den c e  and sever i t y  o f  postope rat ive myalg i as (Bevan 
& Donat i ,  1 9 8 5 ; Lebow i t z  & Ramsey , 1 9 8 9 ; Lee , 1 9 8 4 ; M i l l er & 
Savarese, 1 9 9 0 ; Stoe lt i ng , 1 9 8 9 ) . The e f f i ca c y  of the NDMR 
in b l o ck i ng f as c i cu l at i ons is r e l ated to i ts ab i l ity to 
i nh i b i t the presynapt i c  a ct i on of S ch ( Cho i , Gerg i s ,  & 
Soko l! , 1 9 8 5 ; M i l l e r, 1 9 8 9 ; Standaert, 1 9 8 4 ) . 
Ve curon i um ,  an i ntermed i ate a ct i ng NDMR , has b e en 
stud i ed by sever a l  resear chers as a de f as c i cu l at i ng agent 
(Erko l a, 1 9 9 0 ; Ferr es et a l . , 1 9 8 3 ;  M i ngus, He r l i ch, & 
Es i encraft , 1 9 9 0 ; Osh ita et a l . ,  1 9 9 1) .  It has proven to be 
a saf e  and e f f e ct i ve treatment moda l i ty for attenuat i ng S ch ­
i nduced fasc i cu l at i ons. Ve c uron i um i s  a stero i da l  ana l og o f  
pancuron i um and because o f  i ts '  r i g i d  stru cture, i t  has 
predom i nant l y  post j unct i onal e f f e cts. 
M i vacur i um i s  the newest mus c l e  r e l axant used i n  
anesthes i a  today. It is c l ass i f i ed as a short-ac t i ng NDMR 
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with a duration of a ction b etween S c h  and v e curonium . There 
has not b een any pub lished studies using mivacurium as a 
de fascicu l ating agent . However , it may of f er advantag es 
over vecuronium in attenuating S c h-induced fascicu l ations . 
One possib l e  advantage is mivacurium ' s  potential of having 
pre j un ctiona l e f f e cts . Mivacurium ' s  structure is f l e xib l e  
possib l y  a l lowing it more a c c ess to the pre jun ctiona l 
nicotinic cholinergic rec eptors (Mi l l er & Savarese , 1 9 9 0 ; 
Morgan & Mikhai l , 1 9 92; Stoe lting 1 9 8 9) . 
Purpose 
The purpose of this study was to determine i f  
mivacurium cou l d  b e  used with t h e  same e f ficac y of 
vecuronium to prevent S c h-induc ed fascicul ations with dosage 
regimes based on ideal body weight . 
Research Questions 
This study sought answers to 4 questions: ( 1 )  Can 
mivacurium (Miv) 0 . 02 mg/kg (ide a l  body weight (IBW)) given 
3 minutes prior to the intravenous (IV) administration of 
S ch 1.5 mg/kg (IBW) prevent fascicu l ations in the f a c e , 
upper torso , and upper e xtremities o f  ASA I and ASA II 
patients? (2) Can vecuronium (Ve e) 0. 0 1  mg /kg (IBW) given 3 
minutes prior to the IV administration o f  S c h  1 . 5 mg /kg 
(IBW) prevent f ascicul ations in the fac e , upper torso , and 
upper e xtremities of ASA I and ASA II patients? ( 3 )  Can 2 
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m l  normal saline so lution given 3 minutes prior to the IV 
in j ection of Sch 1 mg/kg ( IBW) prevent fascicul ations in the 
face , upper torso , and upper extremities of ASA I and ASA I I  
patients? ( 4 )  Is one o f  the three agents superior in 
preventing Sch induced fascicu l ations in the f ace , upper 
torso , or upper extremities of ASA I and ASA I I  patients? 
Hypothesis 
There is no significant di f f erence in the attenuation 
of fascicul ations in the face , upper torso , and upper 
extremities of ASA I and ASA I I  patients a fter the IV 
administration of Miv 0 . 0 2  mg/kg ( IBW) or Vee 0 . 0 1 mg/kg 
( IBW) 3 minutes prior to Sch 1 . 5 mg/kg ( IBW) , or norma l 
saline 2 m l  3 minutes prior to Sch 1 . 0  mg/kg ( IBW) . 
De finition of Terms 
ASA I .  American Society o f  Anesthesio logists ( A SA) 
c l ass I patients are hea l th y  and free o f  systemic diseases . 
ASA I I . ASA c l ass I I  patients have mi l d  to moderate 
systemic diseases but have no functiona l limitations . 
Defascicul ations . Defascicul ation or precurarization 
is the IV administration of a subpara l y zing dose of a NDMR 
to prevent fascicul ations . The e f f ectiveness is determined 
by the decrease in observab l e  f ascicul ations . 
Depo l arizing musc l e  r e l axant . A depo l arizing musc l e  
re l axant ( DMR) mimics the action o f  acety lchol ine ( Ach) , 
producing depo l arization of the post j un c tiona l membrane . 
The metabo l ism of a DMR is s l ow compared to A ch, resu l ting 
in sustained depo l ari zation. Ske l et a l  mus c l e  paral ysis 
oc curs because a depo l arized neuromuscu l ar jun c tion ( NMJ ) 
c an not respond to subsequent re l ease o f  A ch . 
Fascicul ations . Fascic u l a tions are transient 
genera lized ske l e t a l  mus c l e  contrac tions. The presenc e  and 
degree of fascicu l a tions were rated on a 0 to 3 s ca l e . 
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A score o f  0 e qua l ed no observab l e  f as cicu l a tions . Very 
fine muscular movements of the e y e l ids , f a c e  and finger tips 
were c l assified as l eve l 1 fasciculations . Leve l 2 
fascicu l a tions were c l assified as minima l muscu l ar movements 
of the fac e , chest and upper extremities . A c l assification 
of 3 was demonstrated by muscu l ar contrac tions whi ch caused 
limb and head movement. 
Ideal Body Weight . The ide a l  body weight ( IBW) is the 
"idea l" weight for a p erson based on height and body frame 
siz e  which is derived from a c tual tab l es . One c a l c u l ation 
of IBW is: IBW ( in ki lograms ( kg)) = a  person ' s  height ( in 
inches) x 2 . 5  - 1 0 0. For e xamp l e , a person that weighs 1 1 0  
kg and is 6 7  inches (in) t a l l has an IBW o f  6 7. 5  kg ( I BW 
(kg) 6 7  ( in) x 2 . 5 - 1 0 0 ) . 
Latency period . The l at en c y  period is that amount o f  
time a l l owed t o  e l apse between the administration of drug 
and its onset of a c tion. The l at en c y  period for NDMR is 3 
minutes when used as a de fascicul ating agent . 
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M i vacur i um .  M i vacur i um i s  the newe s t  NDMR. Metabo l i s m 
occur s by p s eudocho l i ne s teras e ,  but at a rate s l ower than 
Sch . 
Nondepo l ar i z i nq musc l e  r e l axant s . Nonde po l ar i z i ng 
musc l e  r e l axants compete w i th ace t y lcho l i ne for b i nd i ng 
s i te s  i n  the NMJ and p revent chang e s  i n  the p ermeab i l i ty of 
the pos t j unc t i onal membrane . As a r e su l t , depo l ar i z a t i on 
cannot occur and ske l e t a l  mus c l e  para l ys i s  ensue s . Ske l e t a l  
musc l e  fasc i cu l a t i ons d o  not occur w i th NDMR . 
Succ i nylcho l i ne .  Succ i ny lcho l i ne i s  a depo l ar i z i ng 
mus c l e  r e l axant . Its ons e t  o f  act i on i s  w i th i n  1 m i nute 
w i th comp l et e  recovery in 1 0  m i nutes . The u sua l dos e  o f  Sch 
i s  1 mg/kg . However ,  when a NDMR i s  u s ed for 
de fasc i cu l a t i on , the Sch dos e  i s  i ncrea s ed to 1.5 mg/kg . 
Vecuro n i um . Vecuron i um i s  a NDMR of i ntermed i at e  
durat ion . It i s  a monoquar t ernary s te ro i dal ana l ogue o f  
pancuron ium . 
Var i ab l e s 
Independen t . The i ndependent var i ab l e s are M i v  0 . 0 2 
mg/kg ( IBW ) , V e e  0 . 0 1 mg/kg ( IBW ) ( 3  m i nutes pr ior to Sch 
1.5 mg/kg ( IBW ) ) ,  and normal sa l i n e  s o l ut ion 2 ml ( 3  m i nu t e s  
prior to Sch 1 mg/kg ( IBW ) ) .  
Dependent. The dependent var i a b l e  i s  the occur rence of 
obs ervab l e  musc l e  fasc i cu l at ions of the f ace , upper torso , 
and upper extremi t i e s . 
Limitations 
1 .  An individua l ' s  response to a nondepo l ari zing 
muscl e  r e l axant varie s . 
2. An individua l ' s  r e s pons e  to a depo l arizing musc l e  
r e l axant varies . 
3 .  Fascicu l ations may be too fine and/or too brief to 
be observed . 
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4 .  Parturients , chi l dren , ASA I I I , and ASA I V  patients 
are exc l uded from participation in this study . 
De limitations 
1 .  A b l inded observer accurate ly recorded 
fascicu l ations based on a 0 to 3 rating scal e .  
2 .  A l l sub j ects were random l y  a s s igned to one o f  three 
treatment groups: a contro l group or one of two expe rimenta l 
groups .  As signments were based on a tab l e  of random numbers 
in a doub l e -b linded fashion . 
3 .  For patient saf ety , a l l subj ects with known 
sensitivitie s  to any drugs u s ed in this study were exc l uded . 
4 .  A l l  sub j ects between the age s  o f  1 8  years and 7 5  
years with no significant neuromuscul a r , cardiac , hepatic , 
or renal dis ea s e  were con sidered for pos sib l e  inc l usion to 
this study . 
5. A l l  sub j ects were c l as sified a s  ASA I or ASA I I  and 
having surgica l procedur e s  r equiring general anesthe sia with 
endotrachea l intubation . 
Assumpt i ons 
1. Med i ca t i ons g i ven preoperat i v e l y  and for indu c t ion 
of g enera l anesthes i a  d i d  not a f f e c t  neuromuscu lar 
transm i ss i on . 
2 .  The l at en c y  per i od of 3 m i nu tes was adequate for 
onset of a c t i on of the NDMR and was str i c t l y  adhered in a l l  
sub j e c ts .  
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3. Observers ac curat e l y  re corded mus c l e  fasc i cu l at i ons 
based on a 0 to 3 rat i ng s ca l e .  
4 .  Var i ous indu c t i on drugs and t e c hn i ques d i d  not 
a f f e c t  fasc i cu l a t ions . 
5 .  Mus c l e  f as c i cu l at i ons were a common s i de e f f e c t  o f  
S c h  adm i n istrat i on . 
6 .  Mus c l e  fasc i cu l at i ons were not a typ i ca l  s i de 
e f f e c t  o f  NDMR . 
7 .  Mus c l e  r e l axants were adm i n i stered based on I BW . 
8. The Bro c c a  i ndex , a formu l a  for c a l c u l at ing I BW ,  
was cons istent i n  determ i n ing I BW for a l l sub j e c ts based on 
the i r  he i ght. 
9. The pr i mary anesthe t i s t  corre c t l y  adm i n istered 
sa l ine , M i v , V e e , and S c h  as d i c tated b y  the number ass i gned 
each r espe c t i ve sub j e c t . 
Conc eptual Framework 
Neuromus c u l ar jun c t i on .  The neuromusc u l ar j un c t i on i s  
formed by a pre j un c t i ona l motor nerve end i n g  that i s  
separated from a pos t j unct i ona l membrane of the ske l e tal 





F i gure 1. Schema t i c  representat i on of the neuromuscu lar 
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j unc t i on. Not e. From Bas i cs o f  Anesthes ia ( 2nd ed ) ( p . 9 3 )  
by R .  K .  Stoe l t ing and R .  D .  M i l l er ,  1 9 8 9 , New York: 
Church i l l  L i v ingstone . 
The i n i t iat ion of a neuromuscu lar transm iss i on is 
caused by the arr i va l  of a nerve i mpu lse at the motor nerve 
term ina l  that resu l ts in an inf lux of ca lc ium . Th i s  i n f l ux 
of ca lc ium st i mu lates the neurotransm i t t er ace t y lcho l ine to 
be re l eased. Once re l eased , Ach b inds to the post junc t i ona l 
n i cot i n i c  receptors a l ter ing the permeab i l i t y of the 
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pos t junct ional membrane to pota s s i um and sod i um . Th i s  ion ic 
f l ux and change in permeab i l i t y resu l t s  in  a decrease in the 
tran smembrane re s t i ng pot en t i a l  to thre s ho l d  potent i a l  ( - 90 
mV to -45 mV ) . Once the thre sho l d  potent i a l  i s  ach i e ved , 
the act i on potent i a l  i s  propagated over the surface of the 
musc l e  f i b er s  resul t i ng in muscu l ar contract ion . 
Acety lcho l i ne i s  metabo l i z ed w i th i n  1 5  mSec by 
ace t y l cho l i ne s t era s e , thereby r e s tor i ng r e s t i ng membrane 
potent i a l  and permeab i l i t y and pre vent i ng sus ta i ned muscu l ar 
contrac t i on . Acety lcho l i ne s t erase i s  l ocated i n  the fo l d s  
o f  t h e  pos t j unct i ona l membrane. 
N i cot i n ic cho l i nerg ic receptors are the mos t  i mportant 
s i t e s  of act i on of musc l e  r e l axan t s . The s e  receptors are 
located both pre junct ional l y  and pos t j unct i ona l l y .  The 
pre junct i ona l receptors i nf l uence the r e l ease of 
ace ty lcho l i ne . The pos t j unct i ona l receptors are located 
exac t l y  oppos i te the pre j unct ional receptor s . The 
pos t j unct ional receptors are l arge g l ycoprot e i ns . Each 
receptor cons i s t s  of 5 prot e i n  subun i t s , 2 a l pha , 1 each of 
beta , de l ta, and gamma. The s e  subun i t s are arranged i n  such 
a way that a channe l i s  formed a l l ow i ng the i on ic f l ux of 
pota s s i um and sod i um to occur acro s s  the ce l l  membrane ( s ee 
F i gure 2 ) .  






F igure 2 .  Postjunct i ona l n icot i n i c  cho l i nerg i c  receptor s . 
Note . From Bas ics of Ane sthe s i a  ( 2nd ed ) (p . 93) by R. K. 
Sto e l t i ng and R .  D .  M i l l er ,  1 9 8 9 , New York : Church i l l  
L i v i ng stone . 
The two a lpha subun i t s  are the b i nd i ng s i tes for Ach 
and musc l e  r e l axants . For e xamp l e , Sch m i m i cs Ach when i t  
i s  bound to the a lpha subun i t s  and perm i t s  the i o n  channe l 
to rema i n  open . Howev er, because Sch i s  metabo l ized s lower 
than Ach there i s  pro l onged depo l ar i z at i on . Occupat i on of 
the a lpha subun i t s  by a NDMR cau s e s  the chann e l  to rema i n  
c l o s ed , thus muscul ar contract i on cannot occur. Large 
overdosages of NDMRs can a l so p lug the chann e l  and prevent 
normal ion i c  f lux from occurr i n g . 
Ske l e tal musc l e  fasc icu l a t i ons . The or i g i n  of Sch 
i nduced ske l etal musc l e  fasc i cu l at ions has been the source 
of controvers y  for man y years . I t  was or i g i na l l y  b e l i eved 
to be the resu l t  of a s ynchronous depo l ar i zat i on of the 
pos t s ynap t i c  membrane of i nd i v i dua l musc l e  ce l l s  by Sch . 
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Th i s  exp l anat ion i s  unacceptab l e  for t hree reasons: 1 )  the 
a s ynchronous depo l ar i zat i on of i nd i v i dua l muscl e  ce l l s  are 
not observab l e  externa l l y ,  2 )  ent ire motor un i t s (300 -2000 
musc l e  ce l l s )  are act i vated s i mu l taneous l y ,  and 3 )  
fasc icu l a t ions occur repeat ed l y  i n  the s ame area o f  the 
musc l e . Over the pas t  3 decades , accumu l at i on of 
pharmaco log i c  i n format ion sugg e s t s  that nondepo l ar i z i ng and 
depo l ar i z i n g  musc l e  re l axants have many s i t e s  of act i on at 
the NMJ . The e f f icacy of a NDMR i n  b lock i ng Sch- i nduced 
fasc i cu l at i ons i s  r e l ated to i t s  ab i l i ty to i nh i b i t  the 
pre s ynapt i c  act i on of Sch ( Cho i , Gerg i s ,  & Soko l l ,  1 9 8 5 ; 
Lebow i t z  & Rams ey , 1 9 8 9; M i l l er & Savare s e , 1 9 90 ; S toe l t i n g  
& M i l l er ,  1 9 8 9 ) . 
Depo l ar i z i ng musc l e  r e l axant s .  Depo l ar i z i ng muscl e  
re l axants m i m i c  Ach . That i s ,  they b i nd to the a lpha 
subun i t s of the cho l i nerg i c  receptor . However , the 
me tabo l i sm o f  depo l ar i z i ng musc l e  r e l axan t s  i s  v ery long 
compared to the metabo l i sm of Ach . The resu l t i ng 
depo l ar i zat ion of the pos t s ynapt ic membrane perm i t s  a 
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pro longed ionic f l ux that prevents repo l arization of the 
musc l e  membrane from occurring. Without repo l arization , the 
musc l e  membrane i s  unab l e  to re spond to further re l eases of 
Ach and muscl e  re l axation continues for severa l minute s  
( Lebowitz & Rams ey , 1 9 8 9 ; Mi l l er, 1 9 8 9 ; Mi l l er & Savare s e , 
1 9 90 ; Sto e l ting, 1 9 9 1 ; Stoe lting & Mi l l er, 1 9 8 9 ) . 
Nondepo l arizing musc l e  r e l axants . Nondepo l arizing 
musc l e  re l axants compete with Ach for the a lpha subunits 
binding sites of the cho linergic receptor . Once bound , 
NDMRs a lter the permeabi lity of the ion channe l prev enting 
the ionic f l ux . Depol ari zation of the musc l e  membrane i s  
prevented and t h e  musc l e  remains f l accid . Ske l etal musc l e  
contraction cannot occur unti l the NDMR unbinds from the 
a lpha subunits and diffus e s  away from the receptor site . 
This vacant receptor site is now avai l ab l e  to bind with Ach 
to permit the ionic f l ux and depo l arization to reoccur 
( Lebowitz & Rams e y , 1 9 8 9 ; Mi l l er, 1 9 8 9 ; Stoe lting & Mi l l er, 
1 9 8 9 ) . 
The rationa l e  for administering a defascicul ating dos e 
of a NDMR is to prevent fascicul ations from occurring by 
occupying the a l pha receptors on the pre s ynaptic cho l inergic 
receptor . The efficacy of NDMR pre venting Sch induced 
fascicul ations depends on its abi l ity to b l ock the 
pre s ynaptic effect of Sch ( Le bowitz & Ram s e y, 1 9 8 9 ; Mi l l er & 
Savar e s e, 1 9 90 ) .  
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Adminis tration of musc l e  re l axant s based on idea l body 
weight . Musc l e  re l axant s are high l y  ioni zed at physio logic 
pH and pos s e s s  limited lipid solubi lity . Becaus e  of their 
hydrophilic nature , the vo l ume of di s tribution is smal l ,  
being limited to the e xtrace l l u l ar f l uid . A s  a resu l t  of 
this hydrophi licity , musc l e  re l axant dosages shou l d  be 
ca lcul ated on I BW ins t ead of actua l body weight ( Cheymo l , 
1 9 8 8 ) . 
Musc l e  re l axan t s  do not cros s  lipid membranes becau se 
they pos s e s s  at l ea s t  one positiv e l y  charged ammonium group 
and are u s ua l l y  l arge mo l ecu l e s. However , the l arge aqueous 
pores in the s y s t emic vascu l a ture a l l ow the musc l e  re l axan t s  
acc e s s  t o  t h e  neuromuscu l ar j unction where t h e y  readi l y  bind 
to the cho linergic receptors ( Guyton , 1 9 9 1 ; S toe l ting , 
1 9 9 1 )  . 
To prevent musc l e  re l axant overdo s e s  the I BW s hou l d  b e  
u s ed becaus e  it more c l os e l y  corre l a t e s  to t h e  l ean body 
weight. The actua l body weight has two components , l ean 
weight and fat t y  weight . Dos e s  of hydrophi lic drug s  (i . e . , 
musc l e  re l axan t s ) ca lcul ated on actual body weight are 
actua l l y  overdo s e s  becaus e  they do not cro s s  lipophi lic 
membran e s  (i . e . , fatty tis sue ) ( Cheymo l , 1 9 8 8 ) . 
Overdosing with a defascicul ating dos e  of a NDMR can 
r e su l t  in apnea , partial para l ysis , and patient anxie t y . A 
Sch overdos e  resu l ts in an increase in the intensity of 
muscu l ar fascicul ations and a pro longed musc l e  para l ysis 
( Bevan & Dona t i , 1 9 8 5 ; M i l l er & Savare s e , 1 9 9 0 ; Stoe l t i ng , 
1 9 9 1 ) . 
Summary 
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I t  has b e come s tandard pract i c e  to use defas c i cu l at i ng 
dos e s  of NDMR to prevent S ch- i nduced f as c i culat ions . The 
e f f i ca c y  of these dos e s  i s  re l ated to the i r  ab i l i t y to b lo c k  
t h e  pre s ynapt i c  e f f e c t  of S c h . A l so , the use of I BW to 
c a l cu l ate the dos e s  of mus c l e  re l axan t s  prevents overdo s i ng 
of the s e  drugs . 
Ve curon ium wa s chosen for th i s  s tudy for 3 reasons . 
F i r s t , Vee i s  frequent l y  used to prov i de mus c l e  re l axat i on 
dur i ng g enera l anesthe s i a . S e cond l y , i t  has proven i t s e l f  
to b e  a safe and e f f e c t i v e agent i n  prevent i ng S ch- i nduced 
fas c i cu l a t ions . Las t l y ,  b e c au s e  of i t s' r i g i d  s truc ture , i t  
has predom i nant l y  pos t junc t i ona l e f f e c t s . M i vacur i um was 
s e l e c ted be cause there are no pub l i shed s tud i e s  on i t s' use 
as a defas c i cu l a t i ng agen t . A l so ,  i t  has the potent i a l  for 
an enhanced pre j un c t i onal e f f e c t  when compared to Vee . 
Chapter Two 
Re v i ew of the L i terature 
Muscle Fasc iculat i ons 
There has been cons i derab l e  controver s y  over the or i g in 
of Sch- induced fasc icula t i ons . I t  was or i g inally bel i e ved 
to be the re sult of Sch- i nduced a s ynchronous depolar i za t i on 
of the pos t s ynapt ic membrane of ind i v i dual cells ( Cho i , 
Gerg i s , & Sokol , 1 9 8 5 ) . Others be l i eved that depolar i za t i on 
of the muscle endplat e  led to local act ion poten t i als that 
spread to ad j acent membranes , caus ing uncoordinated muscu l ar 
contrac t i ons ( Dr i pps , Eckenho f f , & Vandam , 1 9 82 ) . 
Over the pas t  3 decade s  there have be en an accumulat i on 
of pharmacolog i cal data that sugg e s t  chol inerg i c  agon i s t s  
have act i on s  on t h e  pos t s ynap t i c  neuromuscular j unc t i on and 
on the pre junc t i onal nerve term i nal i t s el f . R i k er ( 1 9 7 5 ) , 
and Standaert and Adams ( 1 9 6 5 )  demonstrated the pre s ence o f  
chol inerg ic receptors both pre - and pos t j unc t i onally . The ir 
res earch sug g e s t ed the or i g in of Sch - i nduced fasciculat ion s  
w a s  t h e  re sult of pre junct i onal chol inerg i c  receptor 
act i va t i on . Hartman , Flamengo , and R i ker ( 1 9 8 6 )  found the 
pre junc t i onal receptors in fluenced the release of Ach . They 
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demon s trated a f e edback me chan i s m i n  wh i c h cho l i nerg i c  
agon i s t s  c aused an i n crease i n  the re l ea s e  o f  A c h  and 
antagon i s t s  de creased or b locked i t ' s  re l eas e . These 
a c t ions were demons trated when Sch , an agon i s t , was g i ven 
and produced fa s c i c u l a t ions , and when d- tubocurar i ne, an 
antagon i s t , was g i ven as a pre treatment and f as c i cu l at ions 
were prevented . 
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Fas c i cu l at ions c an b e  d e s c r i bed a s  the syn chron i z ed 
contrac t ions of a l l mus c l e  c e l l s  in a motor un i t  wh i ch are 
produced by the s t i mu l a t i on of the pre jun c t i ona l cho l i nerg i c  
rec eptors o f  a motor nerve t erm i na l . I t  has been 
demonstrated repeat ed l y  that Sch- i nduced fasc i cu l a t i ons and 
the i r  att enuat ion oc cur b e c ause depo l ar i z i ng and 
nondepo l ar i z i ng mus c l e  r e l axan t s  a c t  d i re c t l y  on motor nerve 
term i na l s .  The c l i n i ca l  s i gn i f i cance of fas c i cul a t i ons i s  
the i r  proposed re l a t ionsh i p  to the oc currence of 
pos topera t i ve mya l g i as and i ncreased i ntraocu l ar and 
i ntragas tr i c  pre s sures ( S tandaert & R i ker , 1 9 6 7 ) . 
Ve curon i um 
Ve curon i um i s  a monoquat ernary analog of the s t ero i d  
mus c l e  re l axant pancuron i um . I t  i s  an i nt erme d i ate a c t i ng 
NDMR w i th ex c e l l ent card iova s c u l ar s t ab i l i t y and doe s not 
cause the re l e a s e  of h i s tami ne. It i s  metabo l i z ed i n  the 
l i v er and excreted i n  b i l e . Mus c l e  r e l axat ion i s  obta i nab l e  
w i th sma l l er dos e s  than gal l am i ne , dTc , or metocur i ne . The 
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onset of act i on of Vee i s  3 m i nutes w i th a duration of 2 5  to 
40 m i nutes ( M i l l er ,  1 9 8 4 ) . 
M i vacur i um 
M i vacur i um i s  a benzy l i soqu i no l i ne der i vat i v e . I t  i s  
the newe s t  of the NDMR s . M i vacur i um i s  a short act i ng NDMR 
w i th an ons e t  t i me of 2. 5 to 3 m i nutes and a durat ion of 2 0  
t o  3 0  m i nute s . I t  does cau s e  the re l ease of h i s tam i ne but 
to a much l e s s  degree than dTc . Metabo l i sm occurs from the 
enzyme p s eudocho l i ne s tera se and m i n i ma l l y  by true 
cho l i ne s t erase ( Morgan & M i kha i l, 1 9 92 ) .  
Prev ious Stud i e s on the U s e  of NDMRs a s  Pre treatments 
Ga l l am i ne . Church i l l -Dav i d son ( 1 9 5 4 )  was the f i r s t  to 
as soc iate pos toperat i ve mya l g i a  w i th Sch- i nduced 
fasc i cu l a t ions . He at t empted to corre l ate the s e ver i t y of 
the pos toperat i ve mya l g i a  w i th the i ntens i t y of the 
fasc icu l at i ons . There were 3 groups i n  th i s  s tudy . Group I 
( n  
= 32 ) were outpat i ent s . Group I I  ( n  = 3 6 ) were 
i npat i en t s  conf i ned to bed for 48 hours pos toperat i v e l y . 
Group I I I  (n = 15 ) were a l so outpat i ents . Groups I and I I  
rec e i ved Sch for musc l e  re l axat i on w i t hout any pretreatment . 
Group I I I  rece i ved ga l l am i ne 4 0  mg i mmed i ate l y  b efore Sch . 
Demographic data was s i m i l ar between a l l  group s . 
Groups I and I I  had a 1 0 0 %  i nc i dence of fasc i cu l a t i ons and a 
6 6 %  and 13. 9 %  i nc i dence of pos toperat i ve mya l g i a ,  
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respe c t i ve l y .  Group I I I  had no v i s i b l e  fas c i culat ions but a 
40% i n c i dence of pos toperat i ve mya l g i a . Church i l l -Dav i dson 
conc luded that i f  Sch i s  used for mus c l e  r e l axat i on dur i ng 
outpat i ent procedure s ,  i t  shou l d  be pre c eded by gal l am i ne 4 0  
mg . He a l so con c luded that the abo l i t i on of f a s c i cu l a t ions 
reduced the i nc i d e n c e  and s e v er i ty of pos toperat i ve mya l g i a . 
Th i s  c l as s i c  s tudy sparked i nt ere s t  i n  us i ng NDMRs as 
pretreatments in prevent i ng Sch- i nduced fas c i culat ions . 
Bur t l e s  and Tuns ta l l  ( 1 9 6 1 )  redu c ed the ga l l am i ne dose from 
40 mg to 8 mg and compared i t  w i th 5 mg of Sch . The 1 7 4 
pat i ents s tud i ed were d i v i ded i nto three groups . Group I 
(n 6 1 )  re c e i v ed norma l s a l i ne pr i or to Sch . Group I I  
(n 5 6 )  re c e i ved 5 mg Sch pr i or to a ful l r e l ax i ng dose of 
Sch . Group I I I  (n = 5 7 )  r e c e i ved ga l l am i ne 8 mg pr i or to 
Sch . Group I ( s a l i ne group ) s erved as contro l s . The 
authors used a b l i nded me thodo logy for th i s  s tudy . 
The i nc i dence of fa s c i culat ions i n  Group I was 82% , 
Group I I  6 8 % , and Group I I I  3 1 % . The redu c t ion of 
fas c i culat ions in Group I I I  was s i gn i f i cant ( �  < . 0 1 ) . One 
error of the s tudy the res earchers i dent i f i ed was the 
f a i lure to contro l the t i me i nt erva l between the 
pre treatment and the adm i n i s trat i on o f  S c h. The t i me 
i nt erva l they att empted to adhere to was 3 m i nutes ; however , 
they acknow l edged that at t i mes i t  was shorter or longer . 
Mas e y , G l az e brook , and Goat ( 1 9 83 )  e s s ent i a l l y  
dup l i cated Bur t l e s  and Tuns tal l's res earch , however , they 
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doub l ed the gal l a m i n e  and Sch dos e s . F ifty pat i ents were 
random l y  d i v i ded i nt o  two groups . Group I (n = 25 ) re c e i ved 
Sch 10 mg 1 m i nute b efore Sch 1 mgjkg . Group I I  (n = 25 ) 
re c e i ved g a l l am i ne 20 mg 3 m i nutes pr i or to an i ntuba t i ng 
dose of Sch ( 1  mg/kg ) . 
Fas c i cu l at i on s  o c curred i n  20 % of Group I I  and 80% of 
Group I .  The authors conc luded that pre treatment w i th Sch 
was i neffe c t i ve i n  prevent i ng fas c i cul at i ons . They a l s o 
stated that though gal l am i ne s i gn i f i cant l y  reduced 
fas c i cu l at i ons , i ntubat i on cond i t i ons were not a s  
sat i sfactory a s  w i th n o  pre treatment . The author s  used S c h  
1 mg/kg as a n  i ntubat i ng dose after t h e  pretreatment w i th 
ga l l am i ne . They conc l uded the dose of S c h  shou l d  be 1 . 5  
mg/kg after a NDMR i s  used for pre treatment . 
d-Tubocurar i ne . As i n tere s t  i ncreased i n  the 
re l a t i on s h i p  of S c h- i nduc e d  fas c i cu l at i ons and po s toperat i v e 
mya l g i a s , o ther NDMRs were s tud i ed i n  a t tempt s  to decrease 
both . A popu l ar NDMR of the t i me was d-tubocurar i ne ( dTc ) . 
Lamoreaux , Karl , and Urbach ( 1 9 60 ) d i v i ded 1 13 ma l e  pat i ents 
i nto 4 group s . Group I (g 
s i ng l e  bolus . Group I I  (g 
Sch 5 0  mg . Group I I I  (n 
2 5 )  re c e i ved S c h  5 0  mg a s  a 
20 ) r e c e i ved dTc 3 mg pr i or to 
3 5 )  r e c e i ved Sch 0 . 2% s o l ut i on by 
s l ow i nfus i on .  Group I V  (n = 3 3 )  re c e i v ed dTc 3 mg pr i or to 
Sch 0 . 2% s o l u t i on by s l ow i nfus i on .  
Fas c i cu l a t i ons on l y  o c curred i n  Group I .  Pos t operat i ve 
mya l g i a  o c curred i n  40% of pat i en t s  i n  Group I ,  1 4% i n  Group 
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I I I ,  and 1 8 % i n  Group I V . There were no pos toperat i ve 
mya l g i a s  reported i n  Group I I . The y con c l uded that the 
speed of i n j e c t ion and concentrat ion of Sch contr i buted to 
the oc currence of fas c i cu l a t i on s  and the i n c i dence of 
postoperat i ve myal g i a .  The i r  resu l t s fa i l ed to demonstrate 
a corre l a t i on between the sever i ty of mus c u l ar 
fa s c i cul a t i ons and the deve lopment of pos toperat i ve mya l g i a . 
Another s tudy employ i ng dTc for def a s c i c u l a t ion was 
performed by Benn i ke and N i e l sen ( 1 9 6 4 ) . Three hundred 
pat i ents were d i v i ded i nto 3 group s . Group I (n = 1 0 0 )  
pat i ents were anesthe t i z e d  w i thout r e l axant s .  Th i s  group 
wa s i n c luded to s tudy the i n c i dence o f  pos topera t i v e  mya l g i a  
i n  pat i ents who re c e i ved no mus c l e  re l axant s .  Group I I  
(n = 1 0 0 )  r e c e i ved Sch 5 0 - 1 0 0  mg as a s i ng l e  dos e, rap i d l y  
i n j e c ted . Group I I I  (n = 1 0 0 )  re c e i ved dTc 2 to 4 mg 2 
m i nutes pr i or to Sch 5 0 - 1 0 0  mg . The dTc was adapted to bod y  
we i ght, i . e . ,  approx i mat e l y  0 . 0 5 mg/kg . Fa s c i culat ions were 
a s s e s s ed a s  m i l d  ( f ew f as c i culat ions ) ,  moderate ( g enera l i z ed 
fa s c i cu l at ions ) ,  or s ev ere ( so pronounc ed a s  to cause 
movement of the shou l ders and l i mbs ) . 
As expe c t ed , no f a s c i cu l a t ions oc curred i n  Group I .  
Group I I  had a 6 5 %  i nc i dence of f a s c i cu l a t i ons w i th 2 6 %  
be i ng m i l d, 33% b e i ng moderate, and 6 %  be i ng s e vere . I n  
Group I I I , fas c i cu l at ions o c curred 1 4% of t h e  t i me, w i th 1 1 %  
be i ng m i l d and 3 %  be i ng moderate . Aga i n ,  there was no 
s i mp l e  corr e l a t ion between the i ntens i ty of fa s c i cu l at ions 
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and the sever i t y of pos toperat i ve mya l g i a , as some pat i ent s , 
who had no v i s i b l e  fas c i cu l a t i ons deve loped pos toperative 
myal g i a  and v i c e  v ersa . However , there was a de crease i n  
the oc currence of fas c i cu l a t ions and a decreased i nc i dence 
of pos toperat i v e mya l g i a  i n  the group that re c e i ved dTc as a 
pre treatment . 
In 1 9 6 7  Zhorov , M i che l son , Krochal er and Sevad j i an 
i nv e s t i gated the prophy l a c t i c  value of a defas c i cu l at i ng 
dose of 3 NDMRs and neo s t i gm i ne . The pat i en t s  were d i v i ded 
i nto 3 groups of 5 0 . Group I pat i ents were g i ven dTc 
3-5 mg , d i p l ac i n  1 0 - 1 5  mg , or kval i d i l 1 0 - 1 5  mg as 
defas c i cul a t i on dos e s . D i p l a c i n  and kva l i d i l  are 
nondepo l ar i z i n g  mus c l e  re l axants u s ed in the Sov i e t  Union . 
Sch 120 mg was i n j e c ted 6 0 - 8 0  se conds after the 
pretreatment . Group I I  pat i en t s  d i d  not re c e i ve any 
pre treatment but were g i ven neos t i gm i ne 0 . 5 - 0 . 7 5 mg 
i n tramu s c u l ar l y  2 0 -3 0  m i nutes preoperat i ve l y . Group I I I  
pat i ents s erved as contro l s  and d i d  not re c e i v e a NDMR 
pre treatment or neo s t i gm i ne . 
Fas c i culat ions were mos t  preval ent i n  the contro l 
group . They oc curred i n  8 6 %  of the pat i en t s. Group I I  had 
s i m i l ar re sul t s  i n  that fas c i culat ions oc curred 82% of the 
t i me. The i n c i dence of fas c i culat ions was the l ea s t  i n  
group I pat i ents . 
The author s ' data demons trated a cons i s tent f i nd i ng 
compared to pre v i ous s tud i e s . The group that re c e i ved the 
defas c i cu l at i ng dose of a NDMR had fewer and l e s s  i ntense 
fas c i culat ions and the oc currence and s ev er i ty of 
pos toperat i ve mya l g i a  was redu c ed . 
Manch i kant i ( 1 9 8 4 )  compared dTc to d i azepam for 
pre treatment i n  preven t i ng fas c i cu l at ions and myalg i a .  He 
random l y  a s s i gned 5 8 7  pat i en t s  to 6 groups . Group I 
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(n = 9 9 )  pat i ents re c e i ved n o  pre treatment and s erved as 
contro l s . Sch 1 . 0  mg/kg was g i ven for mus c l e  r e l axat ion . 
Group I I  (n = 1 3 1 )  rec e i ved d i az epam 0 . 0 5 mg/kg 4 - 5  m i nutes 
pr i or to Sch 1 . 0  mg/kg . Group I I I  (n = 7 1 )  r e c e i ved 
d i az epam 0. 0 5  mg/kg 8 - 1 0  m i nutes pr i or to Sch 1 . 0  mg/kg . 
Group I V  (n = 9 7 )  re c e i v ed d i a z epam 0 . 1  mg/kg 4 - 5  m i nutes 
pr i or to Sch 1 . 0  mg/kg . Group V (n = 9 3 )  rece i v ed d i az epam 
0.1 mg/kg , 8 - 1 0  m i nutes pr i or to S c h  1 . 0 mg/kg . Group V I  
(n = 9 6 )  rece i ved dTc 0 . 0 5 mg/kg , 4 - 5  m i nutes pr i or t o  Sch 
1. 5 mg/kg . Fas c i cu l at ions were graded on a four po i nt s ca l e  
where 0 = no fas c i culat ions , 1 = j u s t  v i s i b l e  
fas c i culat i ons, 2 = moderate contrac t i ons , and 3 
contrac t i ons . 
v igorous 
Fas c i culat ions were seen i n  9 0 %  of pat i ents i n  the 
contro l group . The fre quency and i ntens i ty of 
fas c i culat i ons were una l t ered by pre treatment w i th d i az epam 
i n  both dos e  ranges and d i fferent t i me i nt erva l s  i n  Groups 
I I  through V .  D-tubocurar i ne was h igh l y  effec t i ve ( £  = 
. 0 0 0 0 0 0 1 )  i n  d i m i n i s h i ng the fre quency from 9 0 %  to 1 5 %  and 
v i gorous contra c t ions from 3 1 %  to 1 % . 
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Th i s  s tudy demons trated that pr i or adm i n i s trat ion of 
d i az epam 0 . 0 5  mg/kg or 0 . 1  mg/kg g i v en e i ther 4 - 5  or 8 - 1 0 
m i nutes pr i or to Sch was i ne f fect i ve i n  a l t er i ng the 
frequency of i ntens i t y of fascicu l a t ions . I t  a l so i nd icated 
that pretreatment w i th dTc was h i gh l y  e f f ect i ve i n  
d i m i n i s h i ng the frequency and i ntens i t y  of fasc icu l a t ions . 
The author conc l uded that defascicu l a t i ng w i th dTc wa s 
super ior to pretreatment w i th d i az e pam and shou l d  be the 
method of cho ice for pre vent i on of Sch - i nduced 
fascicu l a t ions . 
Pancuron i um . By the ear l y  1 9 70 s , pancuron ium had 
entered the c l i n ical anesthe t i c  arena as the newest NDMR . 
At the same t i me , concerns sur faced that pre treatments w i th 
NDMRs i ncreased the d i f f i cu l t y  o f  trachea l i ntubat ion by 
antagon i z i ng Sch depo l ar i zat ion . Cu l l en ( 1 9 7 1 )  stud i e d  1 5 8  
pa t i ents to determ i ne the comb i nat ion o f  drugs, dos e , and 
t i me i n terval that wou l d  att enuate Sch - i nduced 
fasc i cu l a t ions but reta i n  exce l l ent cond i t ions for tracheal 
i ntubat ion . I n  th i s  s tudy , 1 5 8  ma l e  and f ema l e  pat i ents 
( ASA I or IE)  were d i v i ded i nto 13 group s .  Sch was s tud i ed 
at two dos age l eve l s  of 1 and 1 . 5 mg/kg a lone and i n  
comb i nat i on w i th dTc ( 1 . 5  and 3 mg ) , pancuron ium ( 0 . 5  and 1 
mg ) , or gal l am i ne ( 5 , 10 , 20 , and 40 mg ) . The pretreatment 
reg imes were s tud i ed at two t i me i nterva l s  of 3 and 7 
m i nutes pr i or to Sch . 
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Fas c i cu l at ions were graded on a 4 po i nt s c a l e  where 0 = 
no v i s i b l e  fas c i cu l a t ions , 1 = v ery f i ne f i nger t i p 
movements , 2 = m i n i ma l  contra c t ions of the trunk and 
extrem i t i e s , and 3 = v i gorous contra c t ions of the trunk and 
extrem i t i e s . Degrees of re l axat i on were a l so a s s e s s ed us i ng 
tracheal i ntubat ion as a s t i mu l u s . Mus c l e  r e l axat i on wa s 
graded on a 4 po i nt s ca l e  where 3 = comp l ete r e l axat i on w i th 
no mus cu l ar re spons e  to i ntubat ion , 2 = s l i ght cough i ng 
movements a s so c i ated w i th contra c t ion of the d i aphragm , 1 
v i gorous coug h i ng w i th contra c t ions of the d i aphragm and 
trunk mus c l es , and 0 = re l axat i on wa s so i nadequate that 
i ntubat ion was i mpo s s i b l e. 
As cou l d  be expec ted w i th 1 3  treatment group s , a l arge 
amount of data was co l l e c ted . A summary of the f i nd i ngs 
fo l lowed . The contro l group had v i gorous fa s c i culat ions , 
but mus c l e  r e l axat i on was comp l e t e . Ga l l am i ne 1 0- 2 0  mg 3 
m i nutes pr i or to Sch 1 . 5  mg/kg both abo l i shed fa s c i cu l at i ons 
and retai ned e x c e l l ent i ntubat i ng cond i t i ons . D­
tubocurar i ne 3 mg 3 m i nutes pr i or to Sch 1 . 5  mg/kg prov i ded 
adequate i ntubat i ng cond i t ions but fas c i culat ions oc curred 
in 40% of pat i en t s . When Sch 1 mg/kg was pre c eded by 
gal l am i ne or dTc , re l axat ion was i nadequate , conf i rm i ng the 
need to i ncrease the Sch dos e  by 5 0 %  when pre treat i ng w i th a 
NDMR . Pre treatment w i th pancuro n i um wa s unsat i sfac tory 
because pat i ents e i ther had fa s c i cu l at ions or were 
i nadequate l y  re l axed . Th i s  s tudy conf i rmed that i ntubat i ng 
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d i ff i cu l t i e s  d i d  oc cur when gal l am i ne o r  d T c  pre c eded Sch 1 
mg/kg. However , the author found that i n creas i ng the Sch 
dosage to 1 . 5  mg and pre treat i ng w i th ga l l am i ne rather than 
dTc or pancuron i um ,  prevented fas c i c u l a t i ons wh i l e a l l ow i ng 
rap i d  onset of e x c e l l ent i ntubat i ng cond i t ions . The author 
re commended ga l l am i ne 1 0 -20 mg 3 m i nutes pr i or to Sch 1 . 5 mg 
as the b e s t  pre treatment reg i me. 
W i g  and Ba l i  ( 1 9 7 9 )  condu c t ed a s tudy that was a i med at 
f i nd i ng the b e s t  do se comb i nat ion based upon a body we i ght 
bas i s  of Sch w i th dTc , ga l l am i ne , and pancuron i um as 
pre treatments . Eas e  of tracheal i ntubat ion , v i s i b l e  mus c l e  
fas c i c u l a t i ons, and pos toperat i ve mya l g i a s were a s s e s s ed . 
The authors were b l i nded unt i l  comp l e t i on of the s tudy. 
Two hundred and ten ASA C l a s s  I adu l t s were d i v i ded 
i nto 21 groups of 1 0  pat i ents each. No premed i ca t i on was 
g i ven to perm i t  better a s s e s sment of i ntubat i ng cond i t ions 
and pos toperat i ve mya l g i as. Sch was i nve s t i gated at three 
dos age l e ve l s  of 1 ,  1 . 5, and 2 . 0  mg/kg a l one as contro l s ,  or 
in comb i na t i on w i th dTc ( 0. 0 5 and 0 . 0 7 mg/kg ) ,  ga l l am i ne 
( 0. 2  and 0 . 4  mg/kg ) , or pan curon i um ( 0 . 0 1 and 0 . 02 mg/kg ) , 
A l l  pre treatment reg i mes were adm i n i s tered 3 m i nutes pr i or 
to Sch . I ndu c t i on of anes the s i a  was s tandard i z ed w i th 
t h i opentone 5 mg/kg . I ntubat ion was at t empted 4 5  s e conds 
after the Sch i n j e c t ion and i ntubat i n g  cond i t i ons were 
a s s e s s ed. V i s i b l e  mus c l e  fas c i c u l a t ions were graded as 
absent , m i l d, moderate , or s e vere . Data about pos toperat i v e  
mya l g i as were obta i ned 6 ,  24 , and 4 8  hours us i ng a 
que s t i onna i r e  i n s trument . 
28 
Pat i en t s  in the three contro l groups had m i l d to s evere 
musc l e  fasc icu l a t i ons but pre treatment w i th NDMRs reduced 
the i nc i dence s i gn i f i can t l y . Both dos e s  of dTc 
s i gn i f i cant l y  reduced the i nc i dence of fasc i cu l a t i on s  to 1 0 %  
and 2 0 % , re spect i ve l y  ( £  = < . 0 0 0 1, and < . 0 1 ) . On l y  one 
group in the gal l am i ne s er i e s  ( ga l l am i ne 0 . 2 mg/kg 3 m i nutes 
pr i or to Sch 1 . 5  mg/kg ) had a 1 0 % i nc i dence of moderate 
fasc icu l a t ions (£ = < . 0 0 1 ) . Pancuron ium at 0 . 0 1 mg/kg was 
much l e s s  effec t i v e  that dTc , ga l l am i ne , or pancuron i um 0 . 02 
mg/kg i n  prevent i ng fasc icu l a t i ons . As the dos e  of Sch was 
i ncreased , the i nc i dence of fasc icu l at ions ros e  from 1 0  to 
1 0 0 % . Pancuron i um 0 . 02 mg/kg comp l ete l y  prevented v i s i b l e  
musc l e  fasc i cu l at ions . 
I ntubat i ng cond i t ions were b e s t  ( 1 0 0 %  succ e s s  rat e )  
when Sch was used a lone a t  the 2 mg/kg l ev e l. Pre treatment 
w i th NDMRs resul ted in a h i gher i nc i dence of d iff i cu l t  
trachea l i ntubat i ons. Idea l cond i t ions were ach i eved on l y  
when Sch 2 mg/kg was adm i n i s tered i n  comb i na t i ons w i th dTc 
0. 0 7  mg/kg ( £  < . 1 ) , ga l l am i ne 0 . 2 mg/kg ( £  < . 1 ) , and 
pancuron i um 0 . 02 mg/kg (£ < . 0 1 ) . I ntubat i on cond i t i ons 
were i nadequate when the Sch dos e  was kept at 1 . 0  or 1 . 5  
mg/kg after pre treatment w i th dTc 0 . 0 5 mg/kg and 0 . 0 7 mg/kg 
(£ < . 0 1 ) , ga l l am i ne 0 . 2 mg/kg and 0 . 4  mg/kg ( £  < . 0 1 ) , and 
pancuron i um 0 . 0 1 mg/kg and 0 . 02 mg/kg (£ < . 0 1 ) . 
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The authors noted that three fac tors m u s t  b e  ob served 
to a c h i eve opt i ma l  benef i t  w i th NDMRs as pre treatments. 
F i rs t , the NDMR must be dos ed based on body we i ght . Se cond , 
the t i me i nt erva l of 3 m i nutes between pre treatment and Sch 
shou l d  be adhered to . La s t , the Sch dos e  shou l d  be 
2 mg/kg . 
After ana l y s i s  of the i r  data , the authors s tated the 
i deal comb i nat ion that pre vented fa s c i c u l at i ons, prov i ded 
the best i ntuba t i ng cond i t ions , and had the lowest i n c i dence 
of pos topera t i v e  mya l g i a s was dTc 0 . 0 7 mg/kg 3 m i nutes pr i or 
to Sch 2 mg/kg . The s e cond b e s t  comb i nat ion was ga l l am i n e  
0 . 2 mg/kg and Sch 2 mg/kg . Pancuron i um 0 . 0 1 mg/kg and 0 . 02 
mg/kg i n  comb i nat ion w i th S c h  2 mg/kg were sat i sfa c tory , 
a l though much l e s s  eff i c i ent than the comb i nat ions w i th dTc 
or gal l am i ne . 
Brodsky , Brock- Utne , and Samue l s  ( 1 9 7 9 )  a l so s tud i ed 
panc uron i um as a pre treatme nt . The i r  s tudy focused on the 
preven t i on of pos toperat i ve myal g i as , but fas c i c u l at i ons and 
i ntubat i ng cond i t ions were a l so obs erved . Forty adu l t  
pat i ents were random l y  d i v i ded i nto two groups . Group I 
(n = 2 0 )  r e c e i ved pan curon i um 1 mg 4 m i nutes pr i or to Sch 
1 . 5 mg/kg . Group I I  ( n  = 20 ) re c e i ved on l y  Sch 1 . 5  mg/kg 
for mus c l e  re l axat ion . I ndu c t i on of anesthe s i a  was 
standard ized w i th t h i opentone 4 mg/kg . Tracheal i ntubat ion 
was performed 60 s e conds after the i n j e c t i on of S ch. The 
res earchers were b l i nded unt i l  the comp l e t ion of the s tudy . 
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Both groups were simi l ar i n  regards t o  demographic 
data . R e l axation wa s adequate for tracheal intubation in 
a l l  patients . The incidence of fas cicu l ations in Group I 
was 2 0 % , but on l y  one of the s e  had vigorou s  fascicul ations . 
I n  Group I I , 9 5 %  of the patients experienced f a s cicu l ations, 
with 6 5 %  demon s trating vigorou s  fas cicul ations . The 
oc c urrence of pos toperative mya lgia was 2 0 %  for Group I and 
35% for Group I I .  There was no corr e l ation with 
fas cicu l ations and the de v e l opment of pos tope rative 
mya lgias . The authors con c l uded the routine practice of 
pretreating with pan curonium 1 mg 4 minut e s  prior to Sch 1 . 5  
mg/kg prevented mus c l e  fascicul ations but did not decrease 
the inciden c e  or severity of pos tope rative myalgias . 
Blitt et a l . ( 1 9 8 1 )  compared dTc , ga l l amine, 
metoc urine , and pancuronium as pretreatment agent s . Eighty 
adu l t  A SA I or ASA I I  patients were random l y  divided into 8 
groups of 1 0  sub j e c t s  each . Six of the 8 groups were given 
a s e l e c ted dose of a NDMR as a pretreatment and 2 groups 
were not pretreated and s erved as contro l s .  The 
pr etreatment r egimes consi s t ed of gal l amine 20 mg , dTc 3 mg , 
pan curonium 0 . 5 mg , and metocurine 1 ,  1 . 5 ,  and 2 mg . A l l  
pretreatment groups r e c eived Sch 1 . 5  mg/kg 3 minutes after 
the NDMR . One cont ro l  group received Sch 1 . 0  mg/kg and the 
other r e c eived Sch 1 . 5  mg/kg . C l inic a l  r e l axation and 
intubating conditions were a s s e s sed on a five point s ca l e  
where 0 = poor r e l axation/ unab l e  to intubate ,  4 = optimum 
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re l axat i on/ e x c e l l ent i ntubat i ng cond i t i ons, and 1 ,  2 ,  and 3 
were vary i ng degrees of r e l axat ion between 0 and 4 .  The 
presence and degree of fa s c i cu l a t i ons were evaluated on a 4 
po i nt s ca l e  where 0 = no fas c i cu l a t i ons, 3 = v i gorous 
fa s c i culat i on s  and 1 and 2 were vary i ng degre es of 
fas c i cu l a t ions between 0 and 3 .  
A l l  8 groups were homogenous w i th regard to age, 
gender, and we i ght. There was no s i gn i f i c ant d i fference 
between groups conc ern i ng i ntubat i ng cond i t ions . A l l 
pat i ents i n  the contro l groups e xh i b i ted fas c i cu l at ions . 
The i nc i dence of fas c i cu l a t i ons was 3 0 %  for the pancuron i um 
group and 1 0 % for the 2 mg metocur i ne group . The on l y  
s tat i s t i ca l l y  s i gn i f i cant d i fference the authors a c h i eved 
regard ing fas c i cu l a t i ons compared the pre treated groups to 
the contro l groups ( E  < . 0 0 1 ) . The authors summar i zed that 
1 mg metocur i ne, 20 mg ga l l am i ne , or 3 mg dTc cou l d  be used 
i nt erchangeab l y  as pre treatments 3 m i nutes pr i or to Sch 1 . 5 
mg/kg . Pan curon i um was aga i n  unsu i tab l e  as a pre treatment 
to prevent Sch- i nduced fas c i cu l at ions . 
By 1 9 8 8  i nt ere s t  aros e  conc ern i ng the s i t e of a c t ion of 
NDMRs at the neuromu s c u l ar junc t ion . Ev i dence sugg e s ted 
that mus c l e  pa i n  was re l ated to the rate of motor end p l at e  
un i t  f i r i ng, not t o  v i s i b l e  fa s c i culat ions . A l so ,  i t  was 
postul ated that NDMRs mod i f i ed fas c i culat ions and 
pos topera t i ve mya l g i a s by prevent i ng pre junct ional 
depo l ar i zat i on and local axon ref l exe s , thereby decrea s i ng 
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the rate o f  motor un i t  f i r i ng .  O ' Su l l i van , W i l l i ams , and 
C a l v e y  ( 1 9 8 8 )  s tud i ed the e f f e c t  of pretreatment w i th Sch , 
ga l l am i ne , or pancuron i um on fas c i cu l at i ons and 
pos toperat i ve myal g i as . Ga l l am i ne was chosen because 
prev i ous r e s earch demons trated a predom i nate l y  pre j unc t i ona l 
e f f e c t  when compared to pancuron i um .  
S i xty adu l t  fema l e  pat i ents were random l y  a s s i gned to 1 
of 4 group s . Group I (n = 1 5 )  r e c e i ved normal s a l i ne 45 
s e conds pr i or to S c h  1 . 5 mg/kg to s e rve as contr o l . Group 
I I  (n = 15) r e c e i ved Sch 1 0  mg 45 s e conds pr i or to Sch 1 . 5 
mg/kg . Group I I I  ( n  = 1 5 )  r e c e i ved ga l l am i ne 2 0  mg 45 
s e conds pr i or to Sch 1 . 5 mg/kg . Group I V  r e c e i ved 
pancuro n i um 1 mg 45 s e c onds pr i or to Sch 1 . 5 mg/kg . 
I nduc t i on o f  ane s the s i a  was s tandard i z ed w i th t h i opentone 
4 mg/kg . The presence and degree of f as c i c u l a t i ons were 
a s s e s s e d  on a 4 p o i n t  rat i ng s c a l e  s i m i l ar to prev i ous 
stud i e s . Postoperat i ve mya l g i a s were a s s e s s ed on a 4 p o i n t  
rat i ng s ca l e  a t  2 4 , 48 , and 7 2  hour s . 
The authors f ound no corre l at i on between the 
fas c i c u l at i on s co r e  and pos toperat i ve mya l g i as at 2 4 , 48 , 
and 7 2  hour s . Some pat i ents had h i gh f as c i c u l at i on s co r e s  
and l ow mya l g i a  s core s , wh i l e  o t h e r s  h a d  l ow fa s c i c u l at i on 
s c ores and h i gh mya l g i a  s c or e s . Pretreatment w i th S c h  
produced no s i gn i f i cant e f f e c t  o n  e i ther t h e  fas c i c u l a t i on 
s c ore or the mya l g i a  s c ore . Gal l am i ne s i gn i f i cant l y  
dec reased the fa s c i c u l at i on s core ( E  < . 05 )  when c ompared to 
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the contr o l  group . Ga l l am i ne a l so decreased the 
postoperat i ve mya l g i a  s cores but the d i f f e rences were not 
s tat i s t i ca l l y  s i gn i f i cant . Pancuron i um decreased the 
fas c i c u l a t i on s c ore but to a l e s s er extent than gal l am i ne . 
Pancuron i um s i gn i f i c ant l y  decreased ( £  < . 0 5 )  the 
pos toperat i v e  mya l g i a  s c o r e s  at 2 4  and 48 hour s . The 
authors c on c l uded the i r  f i nd i ngs were c ons i s t ent w i th 
prev i ous s tud i e s  re gard ing f as c i c u l a t i ons and pos toperat i ve 
mya l g i as . 
Vecuron i um .  Ear l y  i n  the 1 9 8 0 s  vecuron i um arr i ved i n  
the c l i n i ca l  anesthe s i a  arena a s  the newe s t  NDMR. Stud i e s  
soon f o l l owed that eval uated i t s potent i a l  f o r  abo l i s h i ng 
fas c i c u l a t i ons and decreas i ng pos toperat i v e  mya l g i as . 
Ferr e s  et a l . ( 1 9 8 3 )  random l y  d i v i ded 1 9 8  adu l t  ASA I 
pat i ents i nto 9 groups , w i th at l ea s t  2 0  pat i ents i n  each 
group . Pretreatment r e g i mes cons i s t ed o f  ve curon i um 1 mg , 
gal l am i ne 2 0  mg , pancuron i um 1 mg , and dTc 3mg g i ven e i ther 
1 or 2 m i nutes pr i or t o  Sch 1 . 5  mg/kg . A control group 
rec e i ved norma l s a l i ne 1 m i nute pr i or t o  Sch 1 . 5  mg/kg . 
Anesthe s i a  was i nduced w i th th i opentone 5 mg/kg . 
Fas c i c u l a t i ons were graded as absent , moderate , or severe . 
Postoperat i ve mya l g i as were a s s e s s ed at 24 and 48 hours . 
A l l  demograph i c  data between the n i ne groups were 
s i m i l ar w i th regards to age , we i ght , and gende r . The l owest 
frequency o f  pa i n  was f ound in the Vee 2 m i nute group (n = 
2 7 )  wh i ch was 1 8 . 5 % .  The authors noted that the d i f f erence 
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in the overa l l oc currence o f  pos toperat i ve mya l g i a  over the 
48 hours was not d i f f erent whether the pretreatment was 
adm i n i s t ered 1 or 2 m i nutes pr i or to Sch . A l though the 
pretreatment r e g i mes s i gn i f i cant l y  redu c ed the frequen c y  and 
i ntens i ty of fas c i c u l a t i ons (£ < . 0 5 ) , the authors found no 
corre l at i on between fas c i cu l at i ons and the o c curren c e  of 
pos toperat i v e  mya l g i as . 
I n  1 9 9 0 , M i ngus , Herl i c h ,  and E i s enkraf t  s tud i ed the 
i nc i dence o f  fa s c i c u l a t i ons and pos toperat i ve mya l g i as i n  
1 0 0  fema l e  outpat i en t s  who had l aparo s c op i c  surger y . Four 
groups o f  20 pat i ents each were pret reated w i th norma l 
sa l i ne ( Group I ) , dTc 0 . 0 5 mg/kg ( Group I I ) , vecuron i um 
0 . 0 0 6  mgjkg ( Group I I I ) , or m i da z o l am 0 . 0 2 5  mg/kg ( Group I V )  
3 m i nutes pr i or t o  S c h  1 . 5  mg/kg . Group V ( n  = 2 0 )  re c e i ved 
Vee as the s o l e  mus c l e  r e l axant . Th i s  was a prosp e c t i ve , 
doub l e - b l i nded , random i z ed s tudy . Fas c i c u l at i ons were rated 
on a 0 t o  3 s c a l e  s i m i l a r  to prev i ous s tud i e s ( 0  = no 
fas c i cu l at i ons , 1 
fas c i c u l a t i ons , 3 
m i l d fas c i c u l at i ons , 2 = mode rate 
s e vere , v i gorous fas c i cu l at i ons ) . 
Po stoperat i v e  myal g i a  was a l s o s c ored on a 0 to 3 s ca l e  
where 0 = n o  pa i n ,  1 = m i l d ,  2 = moderate ,  and 3 = severe . 
There were no s i gn i f i c ant d i f f erence i n  mean age or 
we i ght between the 5 group s . Data were ana l y z e d  by ana l y s i s  
o f  var i anc e , c h i - s quare , and cont i ngenc y c o e f f i c i ent 
ana l y s i s . A va l ue o f  £ < . 0 5 was cons i dered s i g n i f i c ant . 
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Fas c i c u l at i on s  o c c urred m o s t  frequent l y  i n  the contr o l  
group ( 9 5 % ) , w i th 7 0 %  be i ng rated as moderate . Not 
surpr i s i ng l y , no f a s c i c u l at i ons o c c urred in Group V where 
vecuron i um was the onl y mus c l e  r e l axant u s ed . I n  Groups I I  
and I I I  fa s c i c u l a t i ons o c curred 1 5  and 2 5 % , r e s p e c t i v e l y . 
After ana l y s i s ,  the authors f ound no d i f f erence i n  the 
i n c i dence of f as c i c u l a t i ons among Groups I I , I I I ,  and V ,  or 
between Groups I and IV . The i nc i dence of f as c i c u l a t i ons 
was s i gn i f i cant l y  greater in Groups I and IV than in Groups 
I I ,  I I I , and V (Q = . 0 0 0 1 ) . No s i gn i f i cant d i f f erences i n  
the s e ve r i t y  o f  f as c i c u l a t i ons was f ound between Groups I 
and IV , or between Group s I I , I I I , and V .  The authors a l s o  
i dent i f i ed n o  a s s o c i a t i on between the s ever i t y of 
fa s c i c u l at i ons and the dev e l opment o f  pos toperat i ve mya l g i a  
between the pre treatment group s . The r e s earchers conc l uded 
that vecuron i um ,  but not m i da z o l am , was as e f f e c t i v e  as dTc 
in decrea s i ng the i n c i dence of Sch- i nduced fa s c i c u l a t i ons . 
Osh i ta et a l . ( 1 9 9 1 ) c ompared dTc , pancuron i um ,  and 
vecuron i um as pre treatment reg i me s . Th i r t y - two adu l t s  were 
random l y  a s s i gned t o  1 o f  5 group s . Group I (n = 7 )  
re c e i ved 3 m l  norma l s a l i ne . Group I I  Cn = 7 )  rece i ved S ch 
1 mg/kg . Group I I I  ( n  = 6 )  r e c e i ved dTc 0 . 0 8 mg/kg . Group 
IV Cn = 5 )  rece i ved pancuron i um 0 . 0 1 mg/kg . Group V Cn = 7 )  
r e c e i ved v e curon i um 0 . 0 1 mg/kg . Groups I I I , IV , and V 
rece i ved the pretreatment doses 5 m i nutes pr i or to Sch 1 
mg/kg . 
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Stat i s t i ca l  ana l y s e s  were perf ormed by anal y s i s  of 
var i an c e  and c h i  square ana l y s i s . Ch i - square anal y s i s  was 
perf ormed to c ompare propor t i ons of pat i ents a s s i gned to 
graded categor i e s repres ent i ng i ntens i t y o f  fa s c i c u l a t i ons . 
A £  value o f  < . 0 5 was pre - e s tab l i shed a s  s i gn i f i cant . The 
i nt ens i ty of f as c i c u l at i on s  were evaluated v i s ual l y  and 
s c ored on a 0 to 3 s c a l e  s i m i l ar to the one used by M i ngus , 
Her l i c h ,  and E i s enkra ft ( 1 9 9 0 ) . 
The i n c i dence o f  f as c i c u l at i on s  i n  Group I I  was 1 0 0 % , 
w i th 4 2 %  b e i ng s cored a s  s e vere and 5 8 %  b e i ng moderate . 
Surpr i s i ng l y , the i n c i dence o f  fa s c i c u l at i ons i n  Groups I I I ,  
I V ,  and V was 0 % . Th i s  was a s i gn i f i cant f i nd i ng ( £  < . O S ) . 
The authors summar i z ed that dTc , pancuron i um ,  and ve curon i um 
s i gn i f i c ant l y  and equal l y  abo l i shed Sch- i nduced 
fa s c i c u l at i ons . 
Atracur i um .  I n  the 1 9 8 0 s  a s e c ond i n te rmed i at e - a c t i ng 
NDMR was deve l oped and r e l eased i nto c l i n i c a l  ane s thes i a  
prac t i c e . Th i s  new NDMR was atracur i um .  B y  1 9 8 5  r e s earch 
was conduc ted to test i t s  potent i a l  for fas c i c u l at i on 
attenuat i on and pos topera t i v e  mya l g i a  prevent i on .  
One such study was c ondu c t ed by Budd , S c o t t , B l ogg , and 
Goat ( 1 9 8 5 ) . They s tud i ed 1 0 0  pat i ents who were random l y  
ass i gned to 1 o f  4 group s . Group I ( n  = 2 5 )  re c e i ved 
atracur i um 2 . 5  mg . Group I I  re c e i ved atracur i um 5 mg . 
Group I I I  ( n  = 2 5 )  re c e i ved fazad i n i um 3 . 7 5 mg . Group I V  
Cn = 2 5 )  re c e i ved norma l sa l i ne 3 m l . A l l  pretreatments 
were adm i n i s t ered 3 m i nutes pr i or to Sch 1 mg/kg . 
Fas c i c u l a t i ons were noted as present or absent . 
The i n c i dence o f  fa s c i c u l a t i on s  i n  Group I V  was 9 6 % . 
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I n  Groups I and I I I  fa s c i c u l a t i ons oc curred i n  3 2 %  o f  the 
pat i en t s , wh i l e  in Group I I  fas c i c u l a t i ons o c c urred o n l y  i n  
1 6% o f  pat i ents . The authors noted that the i n c i dence of 
fas c i c u l at i on s  was s i gn i f i cant l y  l e s s  ( £  < . 0 1 )  in a l l  
pre treatment group s . The authors a l s o  i dent i f i ed no 
r e l at i onsh i p  between the o c c urrence o f  fa s c i c u l a t i ons and 
the deve l opment of pos toperat i ve mya l g i a . 
Another s tudy i n  1 9 8 5  was perf ormed by Manc h i kant i e t  
a l . The purpose o f  the s tudy was to e va l uate atracur i um as 
a prophy l ax i s  aga i n s t  Sch- i nduced f as c i c u l a t i ons and 
pos topera t i ve mya l g i a .  E i ghty pat i ents were random l y  
a l l ocated t o  1 o f  4 groups w i th 2 0  pa t i ents i n  each group . 
Pretreatments were adm i n i s tered i n  a dou b l e  b l i nded fas h i on 
and cons i s ted o f  e i ther normal s a l i ne or atracur i um .  
Pat i ents i n  Group s I and I I  s erved a s  contro l s  and 
re c e i ved norma l s a l i ne for pret reatment , f o l l owed 3 m i nutes 
l ater by S c h  1 . 0 mg /kg ( Gr oup I )  or 1 . 5  mg/kg ( Group I I ) . 
Pat i ents i n  Groups I I I  and I V  r e c e i ved atracur i um 0 . 0 5 mg/kg 
pre treatment , f o l l owed 3 m i nutes l ater by Sch 1 . 0  mg/kg 
( Group I I I )  or 1 . 5 mg/kg ( Group I V ) . The i n tens i t y of 
fas c i c u l at i ons was eval uated v i s ua l l y  and s c ored on a 0 to 3 
rat i ng s c a l e . The s c a l e  was the same as the one u s ed b y  
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Manch i kant i ( 1 9 8 4 ) . Pos toperat i ve mya l g i a  was eval uated at 
2 4  and 48 hours pos toperat i ve l y . 
Stat i s t i ca l  ana l y s e s  were performed by ana l y s i s  o f  
var i an c e  ch i s quare ana l y s i s . Overa l l  and f o l l ow-up c h i  
s quare anal ys i s  were perf ormed t o  compare propor t i ons o f  
pat i en t s  i n  t h e  4 groups a s s i gned to graded categor i e s 
represe nt i ng i ntens i t y o f  fas c i c u l a t i ons . Re s u l t s  were 
cons i dered s tat i s t i ca l l y  s i gn i f i cant i f  £ va l u e s  were < . 0 5 .  
Demograph i c  data d i d  not d i f f er s i gni f i c ant l y  between 
the 4 group s . There were s i gn i f i cant d i f f erences between 
the 4 groups w i th r e s p e c t  to mean fa s c i c u l a t i on i ntens i t y  
( £  = . 0 0 0 3 ) . Groups I I I  and I V  had s i gn i f i cant l y  l ower mean 
fa s c i c u l at i on i ntens i ty than Group I and I I  ( £  < . 0 5 ) . 
The re were no s i gn i f i c ant d i f f eren c e s  between e i ther Group s 
I and I I  or Groups I I I  and I V .  The 4 groups a l s o d i f f ered 
s i gn i f i cant l y  in terms o f  proport i on o f  pat i ents w i th 
fas c i c u l at i ons (£ = . 0 0 3 ) . Groups I I I  and I V  had 
s i gn i f i c an t l y  f ewer pat i ents w i th f as c i c u l a t i ons than the 2 
control  groups (£ < . 0 5 ) . The authors conc l uded that 
a tracur i um was e f f e c t i ve in attenua t i ng S ch - i nduced 
fas c i c u l at i ons . 
I n  1 9 8 7 , So s i s ,  Broad , Lar i j an i , and Marr compared 
atrac ur i um to dTc for preven t i on o f  Sch- i nduced 
f a s c i cu l at i ons . Forty- f our ASA c l a s s  I or I I  women 
undergo i ng laparo s c op i c  surgery were random l y  a s s i gned to 1 
of 3 group s . Group I (n = 1 3 )  re c e i ved atracur i um 
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0 . 0 2 5  mg/kg . Group I I  (n = 1 7 )  r e c e i ved dTc 0 . 0 5 mg/kg . 
Group I I I  C n  1 4 )  rece i ved norma l s a l i ne and s e rved a 
contr o l s . A l l  pretreatments were adm i n i s tered i n  doub l e ­
b l i nded manner and were f o l l owed 3 m i nutes l ater b y  S c h  1 . 5  
mg/kg . 
The presence and i ntens i t y of fas c i c u l a t i ons were 
v i sual l y  a s s e s s ed and s c ored on a 0 to 3 rat i ng s ca l e . Th i s  
s c a l e  had prev i ous l y  been u s ed b y  Manch i kant i ( 1 9 8 4 , 1 9 8 5 ) . 
Mu l t i var i a te anal y s i s  o f  var i anc e , f o l l owed by Duncan ' s  
mul t i p l e  range t e s t  and F i sher ' s  e xa c t  probab i l i t y test were 
performed to detect any s tat i s t i ca l l y  s i gn i f i cant 
d i f f erences in dependent var i ab l e s among the group s . A E 
value o f  < . 0 5 was pre - e s tab l i shed as s i gn i f i cant . 
There were no s i gn i f i c ant d i f f erences between the 
groups in terms of age and we i ght . V i o l ent fas c i c u l at i ons 
were not obs erved in any pat i ent . After atracur i um ,  3 1 %  o f  
t h e  pat i en t s  had m i l d  and 1 5 % had mode rate fas c i c u l a t i ons . 
Fas c i c u l at i ons were m i l d i n  6% and moderate i n  6% o f  
pat i ents i n  t h e  dTc group . I n  the cont r o l  group , 
fas c i c u l a t i ons were m i l d i n  3 6 %  and moderate i n  4 3 %  o f  the 
pat i ents . The authors f ound no corre lat i on between 
f as c i c u l a t i ons and the dev e l opment of pos toperat i ve myal g i a . 
They summar i z ed by s tat i ng that a l though atracur i um was 
s i gn i f i cant l y  better than norma l sa l i ne for attenuat i ng 
f as c i c u l a t i ons , dTc was supe r i or .  
Erko l a  ( 1 9 9 0 )  c ompared atracur i um ,  V e e , dTc , and 
a l curo n i um a s  pretreatments for prevent i ng Sch- i nduced 
fa s c i c u l a t i ons and postoperat i ve mya l g i a s . Two -hundred 
f i f t y  women undergo i ng term i nat i on o f  pr egnan c y  dur ing the 
f i r s t  tr i me s t e r  were random l y  a s s i gned to 1 of 5 groups . 
Each group cons i s ted of 5 0  pat i ents . E i ther a l curon i um 
( 0 . 0 3 mgjkg ) , atracur i um ( 0 . 0 4 mgjkg ) , dTc ( 0 . 0 5 mgjkg ) , or 
Vee ( 0 . 0 1 mgjkg ) was adm i n i s t ered 4 m i nutes pr i or to Sch 
1 . 5  mg/kg . An add i t i onal 5 0  pat i ents were g i ven norma l 
sa l i ne 4 m i nutes pr i or to Sch 1 . 0 mgjkg to s e rve a s  
contro l s . 
After the S c h , the s i t e s  of fas c i c u l a t i ons were 
r e c orded and the i r  i ntens i t y was graded as f o l l ows : 0 
abs ent , 1 = f i ne tremor , 2 = moderate fas c i c u l at i ons , and 
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3 = s trong contrac t i ons . Stat i s t i ca l  anal y s i s  was perf ormed 
us i ng the SPSS /PC+ stat i s t i c a l  program . The one -way 
anal y s i s  o f  var i an c e  ( ANOVA ) was u s ed for parame t r i c  data . 
Kruska l - Wa l l i s  one-way ANOVA and the ch i - s quare t e s t  were 
used for non- paramet r i c  data . The Mann-Wh i tney U - t e s t  was 
used for group c ompar i s ons in Sch- i nduced fas c i cu l at i ons and 
postoperat i ve mya l g i a .  Regre s s i on l i n e s  for c orre l a t i on 
between f as c i cu l at i ons and pos toperat i ve mya l g i a  were 
c a l c u l ated after the l ea s t  squares method . A pre­
estab l i shed l ev e l  o f  E < . 0 5 was c on s i dered as stat i s t i ca l  
s i gn i f i cance . 
There were no demograph i c a l  d i f f erences between the 
groups w i th regard to age and we i ght . A l l  pre treatment 
r e g i m e s  prevented Sch- i nduced fa s c i c u l at i ons better 
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( £  < . 0 0 1 )  than normal s a l i ne . A l curoni um and dTc were more 
e f f e c t i ve (£ < . 0 1 )  than atracur i um or Vee . A l curon i um and 
dTc prevented f as c i c u l a t i ons in 9 0 %  of pat i en t s  wh i l e  
atracur i um and V e e  prevented them i n  6 8 %  o f  pat i ents . 
Compared to the other groups , the s a l i ne group exper i enced 
s i gn i f i cant l y  more (£' < . 0 0 1 )  fa s c i c u l a t i ons and mya l g i a .  
M i vacur i um 
M i vacur ium i s  the newe s t  NDMR to enter the c l i n i ca l  
ane s the s i a  arena . I t  i s  c l as s i f i ed as a short-ac t i ng NDMR 
w i th a dura t i on of a c t i on between Sch and V e e . A rev i ew o f  
the l i t erature found that M i v  h a s  not b e e n  stud i ed as a 
pretreatment to prevent Sch- i nduced fas c i cu l at i ons . 
Three M i nute T i me I nterval 
The opt i ma l  t i me i nterval between the adm i n i s trat i on of 
the NDMR pre treatment and the i ntuba t i ng dose of S c h  has 
been a source o f  d i sagreement . Ferres et a l . ,  ( 1 9 8 3 )  
compared Vee , panc uron i um ,  ga l l am i ne , and dTc as 
pretreatments w i th 1 and 2 m i nute t i me i nterva l s  before Sch 
adm i n i strat i on .  The i r  r e s u l t s  demon s t rated that ga l l am i ne 
was the on l y  NDMR e f f e c t i ve i n  prevent i ng f as c i c u l at i ons . 
Ga l l a m i ne prevented fas c i c u l a t i ons i n  8 0 %  o f  pat i ents at 1 
m i nute and 7 5 %  at 2 m i nute s . Fas c i c u l a t i ons o c curred from 
4 0  to 6 7 %  o f  the t i me when the other NDMRs were 
adm i n i s t ered . 
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I n  another s tudy , O ' Su l l i van , W i l l i ams , and Ca l v e y  
( 1 9 8 8 )  c ompared ga l l am i ne to pancuron i um as pretreatments 1 
m i nute before S c h . The i r  res u l t s  were s i m i lar to Ferres et 
a l . in that ga l l am i ne was e f f e c t i ve in prevent i ng 
fa s c i c u l at i ons but panc uron i um was not . The authors 
sugge sted u s i ng a l onger t i me i nterval i f  the pre treatment 
was not ga l l am i ne . 
Other s tud i e s  have i nve s t i gated l onger t i me i nterva l s .  
Manch i kant i ( 1 9 8 4 )  used a 4 to 5 m i nute i nterval when he 
c ompared dTc to d i a z epam as a pre treatmen t . The r e s u l t s  o f  
th i s  s tudy demon s t rated that d T c  was h i gh l y  e f f e c t i v e  
( E  . 0 0 0 1 ) i n  prevent ing fas c i c u l a t i ons when adm i n i s t ered 4 
to 5 m i nutes pr i or to S c h . The author r e c ommended a t i me 
i nterval o f  at l ea s t  4 m i nutes when u s i ng dTc a s  a 
defas c i c u l ator . 
Erko l a  ( 1 9 9 0 )  a l s o u s ed a 4 m i nute l at e n c y  per i od when 
he c ompared a l curon i um , atracur i um ,  dTc , and Vee as 
pretreatments . The r e s u l t s  o f  th i s  s tudy were c omparab l e  to 
Man c h i kant i ' s  ( 1 9 8 4 )  f i nd i ng s . A l curon i um and dTc prevented 
fas c i c u l a t i ons i n  9 0 %  o f  pat i ents wh i l e  fa s c i c u l at i ons were 
prevented in 68% o f  pat i ents pre treated w i th Vee or 
atracur i um .  The author conc l uded that the 4 m i nute t i me 
i nterval as adequate when u s i ng NDMRs as pre treatment s . 
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The most favorab l e  t i me i nterval i n  prev i ous stud i e s  
has been 3 m i nut e s . Benn i k e  and N i e l s en ( 1 9 6 4 )  i nv e s t i gated 
t i me i n terva l s  o f  2 ,  3 ,  and 8 m i nutes us i ng dTc as the 
pretreatmen t . The authors found the opt i m a l  i nterval for 
prevent i ng fas c i c u l at i ons was 3 m i nut e s . The worst i nterval 
was 8 m i nutes f o l l owed b y  2 m i nutes . 
Th i s  t i me i nterval o f  3 m i nutes was a l s o c on f i rmed to 
be the best when u s i ng NDMRs as pretreatments b y  Takk i , 
Kaus t e , and K j e l i berg ( 1 9 7 2 ) , and Harrow and Lambart ( 1 9 8 4 ) . 
S i n ce the m i d - 1 9 8 0 s , mo s t  r e s earchers have u s ed the 3 m i nute 
l atency per i od f o r  preven t i ng S ch- i nduced fa s c i cu l at i ons 
( B l anc , Va i l l an c ourt , Br i s s on 1 9 8 6 ; Budd , S c o t t , B l ogg & 
Goat , 1 9 8 5 ; Man c h i kant i ,  e t  a l . ,  1 9 8 5 ; Marr & Sos i s  1 9 8 9 ; 
M i ngus , He r l i ch ,  & E i s enkraft 1 9 9 0 ; So s i s , e t . a l . 1 9 8 7 ) . 
Pretreatment Do s e s  Based on I BW 
S i nc e  the c l as s i c  study o f  Church i l l -Da v i d son ( 1 9 5 4 )  
demon strated that 4 0  m g  o f  ga l l am i ne prevented Sch- i ndu ced 
fa s c i c u l a t i on s , a mu l t i tude o f  NDMRs and var i ous dosage 
reg i me s  o f  NDMRs have been man i pu l ated . Some r e s earchers 
u s ed f i xed dose reg i me s  o f  NDMRs as pretreatments ( B l i t t e t  
a l . ,  1 9 8 1 ; Budd , S c o t t , B l ogg , & Goat , 1 9 8 5 ; F e r r e s  et a l . ,  
1 9 8 3 ; Mas e y , G l az e brook , & Goat , 1 9 8 3 ; O ' Sul l i van , W i l l i ams , 
& Calvey , 1 9 8 8 ) . Others have advocated do s e s  o f  NDMR s based 
on body we i ght ( B l an c , Va i l l ancour t , & Br i s son , 1 9 8 6 ; 
Erko l a , 1 9 8 8 ; Erko l a ,  1 9 9 0 ; Manch i kant i et a l . ,  1 9 8 5 ; Marr & 
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Sos i s , 1 9 8 9 ; M i ngus , He r l i c h ,  & E i s enkraf t ,  1 9 9 0 ; Osh i ta et 
a l . ,  1 9 9 1 ; So s i s  e t  a l . , 1 9 8 7 ) . 
A re v i ew o f  the l i te rature fa i l s to i dent i f y a s tudy 
that has used NDMRs as pretr eatments based on I BW . A l s o , no 
s tudy was perf ormed us i ng I BW to ca l c u l ate the i ntubat i ng 
doses o f  S c h . Che ymo l ( 1 9 8 8 )  suggested that hydroph i l i c  
med i cat i on dosages shou l d  be based on I BW .  
Su c c i nyl c ho l i ne D o s e s  
The norma l I V  dose of Sch g i ven to fac i l i tate tracheal 
i ntubat i on is 1 mg/kg . Th i s  is the case when Sch is the 
s o l e  mu s c l e  r e l axant u s ed . However , when NDMRs are 
adm i n i s t ered as pretreatmen ts , the r e c ommended Sch dose i s  
i n creased t o  1 . 5  mg/kg . The rat i ona l e  for the i n creased Sch 
do s e  is  that NDMRs are compet i t i ve antagon i s t s  o f  a Sch­
i nduced b l ock . There fore , for S c h  to overcome th i s  
compet i t i ve antagon i s m the i n i t i a l  I V  dose i s  i nc reased b y  
5 0 %  ( Bevan & Donat i ,  1 9 8 5 ; Cho i , Gerg i s  & Soko l , 1 9 84 ; 
Lebow i t z  & Rams e y , 1 9 8 9 ; M i l l e r , 1 9 8 9 ; M i l l e r & Savarese , 
1 9 9 0 ; Stoe l t i ng , 1 9 9 1 ) . 
Summary 
Th i s  r ev i ew o f  the l i terature demons trated d i f f er i ng 
resu l t s on the e f f i ca c y  o f  u s i ng NDMRs as pre treatments i n  
prevent i ng S ch- i nduced f as c i c u l at i ons . The s t ud i e s  
i nd i cated the presence and i ntens i t y of f as c i c u l a t i ons were 
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reduced w i th NDMRs w i th pre treatment pr i or to Sch . No 
pre v i ous s tudy has u s ed I BW to c a l c u l a t e  mus c l e  r e l axant 
dosage s . Equi potent pretreatment doses o f  M i v  and Vee were 
compared . The present s tudy was undertaken to determ i ne i f  
M i v  cou l d  attenuate Sch- i nduced f as c i c u l at i ons as 
e f f e c t i v e l y  as Vee . 
Chapter Three 
Me thodo l ogy 
Res earch De s ign 
To answer the que s t i on , i s  m i vacur i um as e f f e c t i ve as 
ve curon i um i n  suppre s s i ng su c c i n y l cho l i ne- i ndu ced 
fas c i cu l a t i ons , a qua s i - e xper i mental des i gn was cho s en . A l l 
doses o f  Sch , M i v , and Vee were c a l c u l ated based upon I BW .  
There were 2 exper i mental groups and 1 control group . The 
i ndependent var i a b l e s  Vee 0 . 0 1 mg/kg ( I BW ) and M i v  0 . 0 2 
mg/kg ( I BW ) , were man i pu l ated wh i l e the dependent var i ab l e ,  
Sch- i nduced fa s c i c u l a t i ons , was obs erved . The l atency 
per i od o f  3 m i nutes and the dose of S c h  ( I BW )  were treated 
a s  f i xed var i ab l e s . The contro l group r e c e i v ed a sa l i ne 
p l acebo . Pat i en t s  were random i z ed by u s e  o f  a c omputer 
g enerated tab l e  o f  random numbers . 
Se l e c t i on o f  group a s s i gnments was doub l e  b l i nded i n  
the f o l l ow i ng way . A non-par t i c i pat i ng co l l eague created a 
roster o f  pat i ent numbers ( 1 - 6 0 )  and as s i gned groups ( I ,  I I ,  
or I I I )  based on the tab l e  o f  random numbers . A master l i s t  
o f  pat i ent number s  and group a s s i gnments was made and p l aced 
i n  a s ea l ed env e l ope for future data ana l ys i s . Another copy 
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o f  the roster w i th pa t i ent numbe r s  and group as s i gnments was 
cut i nt o  i nd i v i dual str i p s , fo l ded and p l a c ed i nto a bag . 
Th i s  me thod b l i nded the i nv e s t i gator to the group 
a s s i gnment s . 
The i nv e s t i gator c a l c u l ated a l l  dosages as i f  the 
s ub j e c t  wou l d  re c e i ve a l l  three reg i me s  and pres ented the 
r e search i ns trument to the pr i mary ane s the s i a  prov ider . At 
that po i nt , the prov i der s e l e c ted on f o lded s l i p o f  paper 
from the bag that had both a pat i ent number and treatment 
group number . The pat i ent number was wr i tten on the 
res earch i n s t rument ( s ee Append i x  A ) . Med i cat i ons were 
prepared by the p r i mary anesthe s i a  prov i de r  as d i c tated by 
the s e l e c ted treatment group and the s l i p o f  paper was 
destroyed . 
After wa i ver of consent was obta i ned from the Comm i ttee 
on the Conduct o f  Human R e s ear ch , sub j e cts were s e l e c ted 
from the da i l y  operat i ng room s chedu l e  who met the i nc l us i on 
c r i ter i a .  Each s ub j e c t  was taken t o  the surg i ca l  s u i t e and 
p l aced on the surg i c a l  tab l e . Rout i ne mon i tors were 
attached and preoxygenat i on begun . The p r i mary anesthe s i a  
pro v i der gave h i s /her cho i c e o f  med i c at i on t o  b l un t  
laryngos copy . He/she t h e n  i nf ormed t h e  i nv e s t i gator o f  the 
i n j e c t i on of the defas c i c u l at i ng dose ( t i m e  = 0 m i nu te s )  and 
t i m i ng began u s i ng a wa l l  c l ock l ocated in a l l  surg i ca l  
s u i t e s . A t  2 m i nutes from the i n j e c t i on o f  the 
defas c i c u l a t i ng dose , the anes the s i a  prov i der adm i n i s tered 
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a n  i ndu c t i on d o s e  o f  t h e  ane s t he t i c  of h i s /her cho i c e . Upon 
the l o s s  of l i d re f l ex manual vent i l at i on was attempted ; 
when s uc c e s s f u l , i s o f l urane wa s s tarted at the ane s the s i a  
prov i der ' s  d i s cret i on . A t  3 m i nut e s , the i nve s t i gator 
i ns tructed the anesthe s i a  prov i der to adm i n i ster the S c h . 
The s ub j e c t  was then obs erved for fa s c i cu l at i on s  and 
i ntubated when j udged to be c l i n i ca l l y  appropr iate . Two 
i nv e s t i gators r e corded the i n c i dence and i ntens i t y of 
fa s c i c u l at i ons on a 0 t o  3 rat i ng s c a l e . A s core of 3 
i nd i cated v i gorous mu s c l e  contrac t i ons of the f a c e , upper 
torso , and/or upper extremi t i e s . A s core o f  2 i nd i cated 
moderate mus cu l ar contra c t i ons o f  the face , upper torso , 
and/or upper extrem i t i e s . A s c ore o f  1 indi cated very f i ne 
mu s c u l ar contra c t i ons o f  the f a c e , upper torso , and/or upper 
extrem i t i e s . A s c ore o f  0 i nd i cated no v i s i b l e  
fas c i c u l at i on s . Af ter the sub j e c t  was i ntubated , the 
p r i mary anesthe t i s t  provi ded anes the s i a  at h i s /her 
d i s c r e t i on . 
Popu l at i on, Sampl e ,  and Sett i ng 
A nonprobab i l i t y samp l e  o f  c onven i en c e  was obt a i ned 
from a popu l at i on of pa t i ents underg o i ng e l e c t i ve surgery 
requ i r i ng general endotracheal ane s the s i a  at a 1 0 5 2  bed m i d ­
A t l ant i c  un i ve r s i t y teac h i ng ho s p i ta l . S i xt y  pat i ents were 
chosen who met the f o l l ow i ng c r i t er i a : Adu l t , 1 8 - 7 5  years 
o l d , ASA I or I I  w i thout s i gn i f i cant neuromu s c u l ar , hepat i c ,  
rena l , or card i ov a s c u l a r  d i sease . Partur i ents , c h i l dren , 
ASA I I I  and I V  pat i ents were exc l uded from th i s  study . 
Treatment Groups 
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Group I was the contro l group . Two m i l l i l i t ers of 0 . 9% 
norma l s a l i ne was g i ven 3 m i nutes pr i or to S c h  1 mg/kg 
( I BW ) . Group I I  was g i ven Vee 0 . 0 1 mg/kg ( I BW )  3 m i nutes 
pr i or to S c h  1 . 5  mg/kg ( I BW) . Group I I I  was g i ven Miv 0 . 0 2 
mg/kg ( I BW ) 3 m i nutes pr i or to S c h  1 . 5  mg/kg ( I BW ) . 
Analys i s  o f  Data 
The c on t i nuous var i ab l e s  o f  age , h e i ght , and we i ght 
were ana l y z ed b y  one-way Ana l y s i s  o f  Var i anc e . Counts o f  
t h e  d i s crete var i ab l e s , gender , and fa s c i c u l at i ons , were 
ana l y z ed by Ch i - s quare t e s t s . Overa l l  and f o l l ow-up Ch i ­
square ana l y s e s  were p e r f ormed t o  c ompare propor t i ons o f  
sub j e c t s  i n  the 3 groups a s s i gned to graded categor i e s  
repre sent i n g  intens i ty o f  fas c i c u l at i on s . Resu l t s  were 
cons i dered s t at i s t i ca l l y  s i gn i f i cant i f £ va l u e s  were < . 0 5 .  
Chapt e r  Four 
R e s u l t s  
Ana lys i s  o f  Data 
S i x t y  ASA c l as s  I and I I  general surg i ca l  pat i ents we re 
random l y  as s i gned t o  1 o f  3 groups . Group I Cn = 2 0 )  
r e c e i ved norma l s a l i ne a s  a pretreatment and s erved as 
contro l s . Group I I  Cn 2 0 )  pat i ents r e c e i ved V e e  0 . 0 1 
mg/kg as a pret reatment . Group I I I  Cn = 2 0 )  pati ents 
r e c e i ved M i v  0 . 0 2 mg/kg a s  a pretreatment . The d i chotomous 
var i ab l e s  gender , f as c i c u l at i on s , and intens i t y of 
fas c i c u l at i ons , were ana l yzed by the Ch i - square t e s t  of 
i ndependenc e . The cont i nuous var i ab l e s , age , he i ght , and 
we i ght were ana l y z ed by one -way anal y s i s  of var i an c e . There 
were no s i gn i f i cant d i f f e r e n c e s  between the groups w i th 
regard to age , he i ght , we i gh t , and g ender . 
The age o f  the pat i ents ranged from 1 8  to 7 5  year s . 
Group I I  had the l owest mean age ( 4 2 . 6 5 year s ) . Group I had 
the h i ghest mean age ( 4 8 . 8  year s ) . The s e  d i f f e re n c e s  were 
5 0  
5 1  
not s i gni f i cant (£ = . 3 9 ) . Thus , the groups d i d  not d i f f e r  
w i th r e s p e c t  t o  a g e  ( s e e  Tab l e  1 ) . 
He ight 
No s i gn i f i cant d i f f e rences were found between the 
groups w i th r e s p e c t  to he i ght ( £  = . 4 0 0 9 ) . The mean h e i ght 
was h i ghest in Group I I I  ( 1 7 0 . 6 9 e m )  and l owest in Group I I  
( 1 6 1 . 9 3 e m )  ( s ee Tab l e  1 ) . 
We ight 
The smal l e st mean we i ght was in Group I I I  ( 8 1 . 9 5 kg ) 
and the largest i n  Group I I  ( 8 6 . 6 5 k g ) . No s i gn i f i cant 
d i f f erences were found between the groups w i th r e s p e c t  to 
we i ght ( £  = . 6 5 7 6 )  ( s e e  Tab l e  1 ) . 
Gender 
More f ema l e s  ( 3 3 )  than ma l e s  ( 2 7 )  part i c i pated in th i s  
s tudy . Group I I I  had the l arge s t  number o f  f e ma l e s  ( 1 2 )  and 
Group I the smal l e s t  ( 1 0 ) . The s e  d i f ferences wer e  not 
s i gn i f i cant ( £  = . 8 2 )  ( s e e  Tab l e  1 ) . 
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Table 1 
Demographi c  Variables 
I Age (yr) Weight2 (Kg) Height
3 
(em) Gender 
M +/- SD M +/- SD M +/- SD M/F 
Group I 48 . 8  ± 12 . 4  85 . 4  ± 1 3 . 1  170 . 56 ± 10/10 
9 . 9  
Group I I  42 . 7  ± 1 3 . 2  86 . 7  ± 19 . 9  161 . 93 ± 9/11 
9 . 9  
Group I I I  45 . 6  ± 16 . 0  82 . 0  ± 16 . 6  170 . 69 ± 8/12 
Note . 1 = (E = . 3896) , 2 = (E = . 4009) , 3 = (E = . 6576 ) , 4 = (E = . 82) . 
No signi ficant difference (E > . 05) . M = males , F = females , m = mean , 
SD = standard deviation . 
Fas c i cu l at i ons 
Ch i - s quare anal y s i s  o f  the obs ervab l e  var i ab l e ,  
fas c i c u l a t i ons , demonstrated s i gn i f i cant d i f f erenc e s  between 
the control group and the expe r i mental groups ( £  = . 0 0 0 1 ) . 
However , no s i g n i f i cant d i f f e r e n c e s  were f ound between the 
M i v  and Vee groups ( £  = . 2 0 5 9 ) . The i n c i dence o f  
fas c i cu l at i ons was h i ghest i n  the control group ( 9 0 % )  and 
l owest in the V e e  group ( 40 % )  ( s ee Tab l e  2 ) . 
Tab l e  2 
I n c i dence o f  Fa s c i cu l at i ons 
Group I ( 2 0 )  
( s a l i ne )  
9 0 %  ( 1 8 ) "' 
Group I I  ( 2 0 )  
( V e e )  
4 0 %  ( 8 ) * *  
Group I I I  ( 2 0 )  
( M i v )  
6 0 %  ( 1 2 ) * *  
Note . "' = s i gn i f i cant l y  d i f f erent from "' "' (E = . 0 0 0 1 ) . 
= not s i gn i f i cant l y  d i f f e rent f rom each other ( E  > . 2 0 5 9 ) . 
I ntens i ty o f  fa s c i c u l a t i ons 
The intens i t y o f  f as c i c u l a t i ons were graded on a 4 
p o i nt s ca l e  ( 0  = no obs ervab l e  fas c i c u l a t i ons , 1 = m i l d , 2 
moderat e , and 3 = s e vere fas c i c u l a t i ons ) .  Ch i - square 
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ana l y s i s  revea l ed n o  s i gn i f i cant d i f ferences between the Vee 
and Miv groups (E > . 9 9 9 9 ) . S i gn i f i cant d i f f erences were 
found between the contro l group and treatment groups (E < 
. 0 0 0 1 ) ( s e e  Tab l e  3 ) . I ntens i t y o f  fas c i c u l at i ons was 
l owest in the M i v  group w i th a l l  20 pat i ents exper i en c i ng 
m i l d  or no fas c i c u l at i ons . The contro l group had the most 
i ntense fa s c i c u l at i ons w i th 70% be i ng graded a s  moderate or 
severe ( s e e  Ta� l e  4 ) . 
Tab l e  3 
Fa s c i c u l a t i on I ntens i ty 
Fa s c i c u l a t i on Group I * Group I I  * *  Group I I I  * * *  
S c o r e  ( sa l i n e )  ( Vee ) ( M i v )  
( % )  ( % )  ( % )  
0 2 ( 1 0 )  1 2  ( 6 0 )  8 ( 4 0 )  
1 4 ( 2 0 )  7 ( 3 5 )  1 2  ( 6 0 )  
2 1 1  ( 5 5 )  0 ( 0 )  0 ( 0 )  
3 3 ( 1 5 )  1 ( 5 )  0 ( 0 )  
Note . * *  = S i gni f i cant l y  d i f f erent from * but not 
s i gn i f i cant l y  d i f f e rent from each other . 
Tab l e  4 
I n tens i ty o f  Fas c i c u l at i on S c o r e  Comb i ned 
Fas c i c u l a t i on 
S core 
0 - 1 
2 - 3 
Note . 0 - 1 
severe . 
Group I 
( sa l i n e )  
( 2 0 )  
3 0 %  ( 6 )  
7 0 %  ( 1 4 )  
Group I I  
( Ve e )  
( 2 0 )  
9 5 %  ( 1 9 )  
5 %  ( 1 )  
absent or m i l d  and 2 - 3 
Group I I I  
( M i v )  
( 2 0 )  
1 0 0 %  ( 2 0 )  
0 %  ( 0 )  
moderate or 
54 
Chapter F i v e  
D i s c u s s i on 
I ntrodu c t i on 
Th i s  s tudy sought to determ i n e  i f  M i v  i s  a s  e f f e c t i ve 
as Vee i n  att enuat i ng S c h - i nduced fas c i c u l at i ons . The 
hypothe s i s  t e s t e d  was as fo l l ows : there i s  no s i gn i f i cant 
d i f f erence i n  the i n c i dence o f  fas c i c u l a t i ons in the face , 
upper tor s o , and upper extrem i t i e s o f  ASA I and ASA I I  
pat i ents who r e c e i ved a defa s c i c u l a t i ng dose o f  s a l i n e  
( c ontro l ) , Vee or M i v  ( based on I BW )  p r i or to a n  i ntubat i ng 
dose of S c h  ( a l s o based on I BW ) . Ch i - s quare anal ys i s  
revea l ed s i gn i f i cant d i f f e r e n c e s  ( £  = . 0 0 0 1 )  between the 
contr o l  g roup and the exper i mental groups , w i th regards to 
the i n c i dence and i ntens i t y o f  fa s c i c u l at i ons . Howe ver , no 
s i g n i f i cant d i f f e r e n c e s  were obta i ned between the Vee and 
M i v  groups w i th r e s p e c t  to both the i n c i dence and i ntens i t y 
of fas c i cu l a t i ons ( £  = . 2 0 5 9  and £ > . 9 9 9 9 , r e s pe c t i v e l y ) . 
The r e f ore the hypothe s i s  i s  r e j e c t e d . The s tat i s t i c a l  
anal y s i s  o f  t h e  demograph i c  data determi ned that t h e  groups 
d i d  not d i f f e r  w i th regard to age , h e i ght , we i ght , and 
gender . 
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Corr e l a t i on o f  F i nd i ngs W i th Pr e v i ous Stud i e s 
I n c i dence o f  fa s c i c u l a t i ons . Ch i - square ana l y s i s  o f  
the i n c i dence o f  f as c i c u l at i ons revea l ed s i g n i f i cant 
d i f ferences between the contro l group ( s a l i ne )  and the 
exper i mental groups . Th i s  s tudy demons trated that both 
pretreatments ( Ve e  and M i v )  were s i gn i f i cant l y  better than 
sa l i ne in att enuat i ng S c h - i nduced fas c i c u l a t i ons ( E  = 
. 0 0 0 1 ) . S i gn i f i cant d i f f erenc e s  between the M i v  and Vee 
groups were not found . 
5 6  
The protocol  o f  the pres ent s tudy c l o s e l y  f o l l owed the 
protoc o l s  o f  Erk o l a  ( 1 9 9 0 ) , M i ngus , Her l i ch ,  and E i s enkraft 
( 1 9 9 0 ) , and S o s i s  e t  a l . ( 1 9 8 7 ) , w i th m i nor dev iat i ons . 
Erk o l as ' ( 1 9 9 0 )  s tudy popu l at i on was f ema l e  and the l atency 
per i od was 4 m i nutes . The popu l at i ons o f  M i ngus , Her l i ch ,  
and E i s enkraft ( 1 9 9 0 )  and S o s i s  et a l , ( 1 9 8 7 ) were a l s o 
fema l e  and a l l groups r e c e i ved S c h  1 . 5  mg/kg , the s a l i ne 
( c ontro l )  group i n c l uded . Even w i th the s e  dev i a t i ons , the 
resu l t s  obta i ned i n  th i s  s tudy support the f i nd i ngs of the 
above ment i oned s t ud i e s . That i s ,  a l l  pre treatment r e g i m e s  
at tenuated S ch - i nduced fas c i c u l at i ons s i g n i f i cant l y  b e t ter 
than s a l i n e . A l s o , c ons i s tent w i th the f i nd i n g s  o f  th i s  
s tudy , the prev i ous s tud i e s fa i l ed t o  f i nd a s i gn i f i cant 
d i f ference be tween the NDMR s used as pre treatmen t s . 
I ntens i ty o f  f a s c i c u l at i ons . Ch i - s quare ana l y s i s  
demons trated d i f f e r e n c e s  i n  the i ntens i ty o f  f as c i c u l at i ons 
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between the contro l group and both the exper i mental groups 
( E  < . 0 0 0 1 ) . No s i gn i f i cant d i f f erences were obtai ned 
between the Vee and M i v  groups ( E  > . 9 9 9 9 ) . The struc tured 
obs ervat i on te chn i que used in thi s s tudy to grade the 
i ntens i t y of fas c i c u l a t i ons was used by prev i ous r e s earchers 
( B l i t t e t  a l . ,  1 9 8 1 ; Erko l a , 1 9 9 0 ; Manch i kant i ,  1 9 84 ; 
Manch i kant i et a l . ,  1 9 8 5 ; S o s i s  et a l . ,  1 9 8 7 ) . I n  the 
pres ent s t ud y , the contro l ( sa l i ne )  group expe r i enced 
s i gn i f i cant l y  ( E  < . 0 0 0 1 )  more i ntense fasc i cu l a t i ons than 
the exper i mental groups . A l though the i ntens i t y o f  
fas c i c u l a t i ons was reduced i n  both exper i menta l groups , n o  
stat i s t i ca l l y  s i gn i f i cant d i f f e rences ( E  > . 9 9 9 9 )  between 
them were found . The s e  r e su l t s  are congruent w i th the 
f i nd i ngs o f  prev i ous s t ud i e s ( B l i t t e t  a l . ,  1 9 8 1 ; Erko l a ,  
1 9 9 0 ; Man c h i kant i ,  1 9 84 ; Manc h i kant i e t  a l . ,  1 9 8 5 ; Sos i s  et 
a l . ,  1 9 8 7 ) . 
L i m i ta t i ons 
The ma j or l i m i tat i on o f  th i s  study was t i me . Data 
c o l l e c t i on was l i m i ted to a 6 week per i od when the 
re searcher was a s s i gned t o  a c l i n i ca l  rotat i on at a m i d­
A t l ant i c  u n i vers i t y - based teach i ng ho s p i ta l . Because o f  
t i me constra i nt s , the samp l e  s i z e was r e l a t i ve l y  sma l l  C N 
6 0 ) , w i th on l y  2 0  pat i ents per treatment group . A l s o , 
because M i v  has not prev i ous l y  been stud i ed as a 
pretr eatment to at tenuate S c h - i nduced fas c i cu l a t i ons , 
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general as sumpt i ons shou l d  not b e  drawn due t o  the sma l l  M i v  
exper i mental group ( n  = 2 0 ) . A l arger samp l e  s i z e may have 
been bene f i c i a l . 
Another l i m i tat i on was the fa s c i c u l at i on i ntens i ty 
s c a l e . The presence and degree of fas c i c u l a t i ons were 
graded on a 0 to 3 s ca l e  b y  a s t ruc tured o b s e rvat i on 
techn i que . Th i s  t e chn i que has prev i ous l y  been u s ed by 
s evera l r e s earchers , and wh i l e appear i ng to be a r e l i ab l e  
and va l i d techni que , i t  l i m i t s measurements t o  the 
obs ervat i on s k i l l s o f  the rec order . 
Rec ommendat i ons for Future S tudy 
I n  order to expand the f i nd i n g s  of th i s  s tudy , s evera l  
sugge s t i ons are made f o r  future r e s earch . The f i r s t  
i nv o l ves t h e  l ev e l  of measurement u s e d  f o r  data c o l l ec t i on . 
An i ns trument , such as a myograph , cou l d  be emp l oyed wh i c h 
wou l d  a l l ow for a better de l i neat i on o f  fa s c i c u l at i on 
i ntens i t y . Thi s ,  i n  turn , wou l d  perm i t  more s tr i ngent 
stat i s t i ca l  t e s t i ng . 
A s e cond r e c ommendat i on for future s tudy i nvo l ve s  t i me . 
An adequate amount o f  t i me for data c o l l e c t i on wou l d  a l l ow 
the re s earcher to control any preoperat i v e med i c a t i ons , have 
a l arger samp l e  s i z e , and s tandard i z e the i ndu c t i on 
techni que . 
A t h i rd sugg e s t i on wou l d  be to dup l i cate the p r e s ent 
s tudy and observe for s i de e f f e c t s  wh i ch may o c cur w i th 
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pretr eatments . Pat i ent anx i ety , par t i a l  para l y s i s ,  and 
apnea have been a s s o c i ated w i th pre treatment d o s e s  of NDMRs . 
I t  wou l d  be i ntere s t i ng to de term i ne i f  these s i de e f f e c t s  
wou l d  be att enuated by u s i ng mus c l e  r e l axant d o s e s  based on 
I BW . 
F i na l l y ,  the f i nd i ng o f  the pres ent s tudy have 
supported that pretreatment w i th M i v  i s  an e f f e c t i ve mode of 
att enua t i ng S ch- i nduced fa s c i c u l a t i ons . I t  wou l d  be 
i n tere s t i ng to dup l i c ate prev i ous stud i e s , us i ng M i v , to 
deter m i n e  if it i s  e f f e c t i ve in prev ent i ng mya l g i a s  and 
i n creases in i ntrao c u l ar and i n tragas tr i c  p r e s s ur e s . 
Research o f  th i s  t ype m i ght h e l p  to r e s o l v e some o f  the 
d i s crepanc i e s found f rom the rev i ew o f  prev i ous s tud i e s . 
C l i n i c a l  S ign i f i can c e  
Formu l at i ng a c o s t - e f f e c t i v e  ane s the t i c  p l an i s  
becom i ng ever i mportant w i th the pr i c e o f  hea l th care 
drast i ca l l y  i n creas i ng . The resu l t s  o f  th i s  s tudy 
demons trated that M i v  was as e f f e ct i v e  as Vee in att enuat i ng 
S ch- i nduced fa s c i c u l a t i ons . The c o s t  o f  M i v  i s  $ 8 . 0 4 for a 
5 m l  v i a l  ( 1 0  m g )  and $ 1 2 . 5 6 for a 1 0  m l  v i a l  ( 2 0 m g ) . 
Ve curon i um c o s t s  $ 1 6 . 8 3 for a 1 0  mg v i a l  and must be 
r e cons t i tuted w i th a ste r i l e  d i l uent ( s a l i ne or water ) wh i c h 
adds further c o s t  to the pat i ent . Thus when compar ing 
e qu i val ent pretreatment c o s t , Miv is the supe r i or agent . 
Summary 
The purpose of th i s  s tudy was to determ i ne i f  M i v  was 
as e f f e c t i ve a s  Vee i n  att enuat i ng Sch- i nduced 
fas c i c u l a t i on s . A l though fas c i c u l a t i on s  are not l i f e  
threaten i ng , they have been a s s o c i ated w i th mya l g i a s and 
i n c r e a s e s  in i ntracran i a l , i ntragas t r i c  and i ntrao c u l a r  
pre s s ur e s . The r e f ore , ane sthe s i a  prov i d e r s  attempt to 
att enuate the f a s c i cu l at i ons by g i v i ng s ma l l  s ubpara l y t i c  
d o s e s  o f  NDMRs . Vee and M i vacur i um have therapeut i c  va l ue 
i n  ach i e v i ng th i s  goal . 
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The r e s u l t s o f  th i s  s tudy demons trated that M i v  was a s  
e f f e c t i v e  a s  Vee i n  attenuat i ng Sch- i nduced fas c i c u l a t i on s . 
There were no s i gni f i cant d i f f e r e n c e s  between Vee and Mi v ;  
howe ver , there were s i gn i f i cant d i f f erences when compar i ng 
s a l i n e  to V e e  or M i v . Ve curon i um or M i vacur i um ( g i ven i n  
d o s e s  based o n  I BW )  3 m i nu t e s  pr i or to a n  i ntubat ing d o s e  o f  
S c h  ( a l s o  based o n  I BW )  dec reased t h e  i n c i dence and 
intens i t y of S c h - i nduced fas c i c u l a t i on s . A l s o , M i v  i s  more 
cost e f f e c t i v e than Vee i n  attenuat i ng Sch- i nduced 
fas c i c u l a t i on s . 
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APPENDIX A 
Research Instrument 
Patient Initials Patient Hospital Number 
__
______ _ 
Patient Assigned Study *-----Treatment Group *---------
Age ____ Surgi cal Procedure __ =-���--�---------------
Sex ____ Weight ( lbs) Weight (kgs) -----c:-=:-----::-::-=-:------Height ( in) _____ Ideal Body Weight (Ht . x 2 . 5  - 100) __ __ 






Q!:E_l .  Sal ine 2 ml 
Succinylcholine 1 mg/kg ( IBW) _mg+_ml saline =9ml 
� .  Vecuronium 0 . 01 mg/kg ( IBW) _mg+_ml sal ine =2ml 
Succiny !choline 1 .  5 mg/kg ( IBW) _mg+_ml sal ine =2ml 
Grp I I I . Mivacurium 0 . 01 mg/kg ( IBW) _mg+_ml sal ine = 2ml 
Succinylcholine 1 . 5  mg/kg ( IBW) _mg+_ml sal ine =9ml 
Protocol 
1 .  Obtain permission of primary anaesthesia provider . 
2 .  Review patient chart for study inclusion criteria.  
3 .  Calculate and prepare study treatment drugs . 
4 .  Primary anesthesia provider selects study * and group * from bag . 
5 .  Discard syringes not to be used . 
6 .  Connect routine monitors and begin preoxygenation . 
7 .  Record basel ine vital signs . 
8 .  Begin giving drug (s) of choi ce to blunt laryngoscopy . 
9 .  Time 0 minutes , give pretreatment . 
1 0 .  Time 2 minutes , give induction agent and venti late at loss of l id 
reflex ; turn on Forane . 
1 1 .  Time 3 minutes , give intubating dose of Sch . 
12 . Observe and record fasci culations on the 0 to 3 rating scale . 
13 . Intubate when c l inically appropriate . 
14.  Continue anesthetic regime as di ctated by patient needs . 
Fasci culations 
None (0) 
Fine ( 1 )  ______  
No observable fasci culations 
Fine muscular contractions of the face , upper torso 
and/or upper extremities 
6 7  
Moderate ( 2 ) _  Moderate muscular contractions o f  the face , upper torso 
and/or upper extremities 
Severe (3)  
__ 
_ 
Severe muscular contractions of the face , upper torso 
and/or upper extremities 
V i ta 
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